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ABSTRACT 
 
The C-terminus of the Hsc70 Interacting Protein (CHIP) is a 35kDa homodimeric 
quality control E3 Ubiquitin ligase that occupies a very central position in the maintenance 
of cell homeostasis due to its role in the preservation of the integrity of the proteome. CHIP 
acts as the bridge between the chaperones network and the ubiquitin/proteasome pathway 
due to its functions as both a co-chaperone for heat shock proteins and as an E3 ligase.   
 Although CHIP’s role in several pathologies such as Alzheimer’s, Parkinson and 
Cancer has been established little is still known about this protein and the mechanisms 
that regulate it are not yet well understood. 
 In this study, a canine scFv antibody library was screened against wild type CHIP 
and the CHIP TPR mutant K30A with the goal of selecting scFvs that could then be used 
to image and modulate CHIP’s activity.  
Four different clones were selected by Phage Display technology, purified and 
characterized according to their affinity for the targets and their activity was tested in in 
vitro ubiquitination assays. The scFv fragments were shown to inhibit CHIP’s ubiquitination 
of α-synuclein but not CHIP’s autoubiquitination or p53 ubiquitination, suggesting that 
different intrinsic mechanics may be at play. Additionally, CHIP appeared to induce the 
formation of α-synuclein gel-excluding bands which have been predicted to be either α-
synuclein aggregates or refolded α-synuclein. 
This project has shown that scFvs can be an interesting biological tool that can not 
only be used to design new detection strategies or for possible future therapeutic 
applications but also to produce a better understanding of the molecular dynamics and 
mechanisms that regulate CHIP through the modulation of its activity. 
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RESUMO 
 
C-terminus of the Hsc70 Interacting Protein (CHIP) é uma enzima E3 
homodimérica de 35kDa com uma função relevante na manutenção da homeostasia 
celular devido ao seu envolvimento na preservação da integridade do proteassoma. A 
CHIP funciona como ponte entre a rede de chaperones e a via proteolítica dependente de 
ubiquitina/proteassoma devido às suas funções como co-chaperone de proteinas de 
choque térmico (Hsp) e como ligase de ubiquitina E3.   
 Apesar do envolvimento da CHIP em várias patologias como a Doença de 
Alzheimer, Parkinson ou cancro já ser bem reconhecido, ainda são desconhecidos muitos 
dos mecanismos moleculares que determinam e regulam a atividade desta proteína.  
 Neste estudo, uma biblioteca canina de anticorpos scFv foi rastreada contra a 
CHIP e a sua mutante K30A, com o objetivo de selecionar scFvs que pudessem ser 
usados para a deteção e modulação da atividade da CHIP. 
 Quatro scFv clones diferentes foram selecionados através da tecnologia de Phage 
Display, purificados e caracterizados de acordo com a sua afinidade para os alvos. 
Adicionalmente a sua atividade in vitro foi testada recorrendo-se a ensaios de 
ubiquitinação. 
Os resultados obtidos demonstraram que estes fragmentos scFv eram capazes 
de inibir a ubiquitinação da α-sinucleina pela CHIP, mas não a auto-ubiquitinação da CHIP 
ou a ubiquitinção da p53. Estes resultados sugerem o envolvimento de diferentes 
mecanismos nestes processos de ubiquitinação pela CHIP. 
Adicionalmente demonstrou-se também que a CHIP parece induzir a formação de 
bandas de α-sinucleína que ficam retidas no gel de concentração, as quais poderão ser 
agregados ou ‘refolded’ α-sinucleína. 
Neste projeto foi possivel mostrar que os anticorpos scFv podem ser uma 
ferramenta biológica relevante não só para desenhar novas estratégias de deteção ou 
possíveis terapias, mas também para estudar as dinâmicas moleculares e os mecanismos 
que regulam a CHIP através da modulação da sua atividade. 
 
 
 
 
Palavras-Chave: CHIP; ‘Phage Display’; ScFv; Ubiquitinação; α-sinucleína
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 The Rise of Recombinant Antibodies 
As a fundamental part of the immune system, antibodies, also known as 
immunoglobulins (Igs), are an effective security system against pathogenic organisms or 
toxins that threaten our body due to their ability to correctly find almost any target antigen 
and elicit a neutralization response from the host organism (Murphy et al., 2012). As such 
they are the best “search engines” to detect very small amounts of target molecules, which 
makes them one of the most used tools in research laboratories all over the world. Besides 
their broad use in research techniques, new recombinant technologies have facilitated 
antibody engineering, potentiating their use in diagnostics and as therapeutics for cancer, 
infectious and inflammatory diseases (Chames et al., 2009). 
 
1.1. General Antibody Structure 
 IgG is a bivalent, Y-shaped antibody, 
with a well-established structure (Figure 1) and 
the most abundant antibody in human serum. It 
is also the most common format for antibodies 
in diagnostics and therapeutics. The variable 
regions determine the specificity, diversity and 
affinity of the antigen binding while the constant 
domains mediate the antibody structure, half-
life and effector functions. Within each variable 
domain of the light and heavy chains are three 
hypervariable regions, also known as 
complementary determining regions (CDRs), 
which form loops and exhibit high sequence 
variability, being predominantly responsible for 
antigen recognition. The rest of the VL and VH domains, denominated framework regions, 
are less variable and act as a platform to support the CDR loops (Murphy et al., 2012). 
 However this structure is sometimes unattractive for certain applications, due to 
the effects induced by the Fc domain. For example, unwanted activation of the effector 
functions can lead to cytokine release mediated toxicity and a long serum half-life is 
particularly undesirable in imaging applications, where rapid clearance is required in order 
to improve contrast (Holliger and Hudson, 2005). 
Fab 
Fc Constant region 
Variable region (Fv) 
IgG 
CH 
CH CH 
CH CH 
CH 
CL CL 
VH   VH VL VL 
Figure 1. Basic Structure of the IgG molecule. 
IgG structure comprises two large heavy chains and two smaller light chains. Each light chain presents one variable domain (VL) and one constant domain (CL) while the heavy chains contain one variable domain (VH) and three constant domains (CH). The constant region is coloured blue and the variable regions aredesigned with stripes representing the CDRs.  
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 Smaller antibody fragments were then generated to overcome the limitations of 
monoclonal antibodies (mAbs). Initially, this was accomplished by removing the Fc domain 
using proteolytic treatments with enzymes such as papain or pepsin, yielding Fab and 
F(ab’)2 fragments, respectively (Porter, 1959; Nisonoff et al., 1960). Inbar and colleagues 
were able to obtain a Fv fragment by peptic digestion of a mouse IgA-myeloma (Inbar et 
al., 1972) however the development of general procedures for Fv isolation was met with 
limited success (Kakimoto and Onoue, 1974; Sharon and Givol, 1976; Lin and Putnam, 
1978; Reth et al., 1979; Sen and Beychok, 1986) and Fab antibodies persisted as the 
smallest fragment used for biomedical purposes. Later, advances in recombinant DNA 
technology and antibody engineering led the way to the development of a large variety of 
recombinant antibody (rAb) fragments with unlimited potential for research, diagnostics 
and therapy.  
 
 
 
 
 
Among these fragments can be included Fab, scFv (single chain variable 
fragment), V-domain molecules (Figure 2) as well as camelid VHH and shark V-NAR 
fragments. Compared to mAbs, these minimized antibodies can retain target specificity 
while presenting several advantages such as a smaller size and reduced immunogenicity, 
since they lack the Fc domain; better tissue penetration, rapid blood clearance and lower 
retention time in nontarget tissue, which can be quite beneficial for the purposes of 
radiotherapy and diagnostics. These and other properties can be tailored and manipulated 
to better suit the future application of the fragments (Holliger and Hudson, 2005). The rAb 
fragments can also be easily and cost-effectively cloned and expressed in large quantities 
in bacterial (Skerra and Pluckthun, 1988), plant (Galeffi et al., 2006), insect (Choo et al., 
2002), mammalian and yeast cells (Ho et al., 2006), which makes them more economically 
viable.  
 
1.2. ScFvs and derived multimeric complexes 
 ScFv fragments represent the smallest functional VH-VL domains capable of high-
affinity binding to the antigen and were first developed by Huston and co-workers (Huston 
ScFv 
5’ 
3’ Linker  VH 
Fab 
CH 
VL 
CH 
CL CL 
VH VL 
  VH 
CH 
VL 
F(ab’)2 
  VH 
VL 
Figure 2. Schematic representation of proteolysis and engineered rAb fragments. 
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et al., 1988) and immediately followed by Whitlow and his team (Bird et al., 1988). 
Nowadays, scFvs are the most popular rAb fragment due to their versatility. 
Antibodies in the format of scFv are proteins with a molecular weight varying from 
26 to 30 kDa that have the ability to bind to the target with identical affinity to that of the 
parental mAb (Bird et al., 1988) and consist of one VH and one VL chain connected by a 
flexible peptide linker (Maynard and Georgiou, 2000; Monnier et al., 2013).  
Currently, the most used linkers include sections of glycine and serine residues for 
flexibility and Glutamic acid and lysine charged residues to improve solubility (Whitlow et 
al., 1993). Generally, these sequences are 15 to 20 amino acids long, as scFvs joined by 
a linker with less than 12 amino acids cannot fold into a functional Fv domain (Holliger et 
al., 1993) and should maintain an hydrophilic nature to keep them from interposing within 
or between the variable domains during folding of the scFv (Argos, 1990). The variable 
regions can be associated in either VL-linker-VH or VH-linker-VL orientation, but the latter is 
the most common. This factor deserves some attention as the orientation can impact scFv 
stability, binding to the antigen (Desplancq et al., 1994) and expression efficiency (Merk 
et al., 1999). 
As scFv fragments are small and bind monovalently to their target they often 
present low functional affinity (also termed avidity) and a short in vivo half-life (Fitch et al., 
1999; Mayer et al., 1999). While these properties can be useful for some imaging 
diagnostic techniques, for example, they can compromise the success of these molecules 
as therapeutics agents as these may require higher retention times on the target antigen 
or engagement of multiple receptors in order to activate signal transduction and/or 
apoptosis (Teeling et al., 2004; Linsley, 2005). In order to overcome this problem while 
maintaining optimal size for tissue penetration, scFv antibodies are engineered into 
different types of multimeric complexes for greater binding avidities and better 
pharmacokinetic properties (Goel et al., 2000; May et al., 2012).  
Among the above mentioned complexes it is possible to find minibodies, diabodies, 
triabodies, tetrabodies and bispecific scFv fragments (Figure 3).  
Diabodies, triabodies and tetrabodies are noncovalent molecules that assemble 
due to short linker lengths. ScFv fragments with linkers of three to twelve amino acids will 
have the tendency to dimerize, as the VH chain will associate with the VL chain of another 
scFv forming a diabody (~60kDa) (Holliger et al., 1993). Decreasing the linker length to 
three or less amino acids will induce the scFv association into triabodies (~90kDa) (Iliades 
et al., 1997) or tetrabodies (~120kDa) (Dolezal et al., 2003).  
FCUP DEVELOPING SYNTHETIC TOOLS TO IMAGE AND MODULATE THE ACTIVITY OF CHIP 4  
 
 
 
Multispecific scFv antibodies can be developed by combining two or more scFvs 
with different antigenic targets, enhancing target selectivity and allowing the interaction 
with multiple epitopes within the same molecule or in different targets (Neri et al., 1995; 
Coloma and Morrison, 1997).  
Minibodies consist of multivalent antibody fragments that have been covalently 
linked to self-assembling proteins, for example, amphiphilic helix bundles and leucine 
zippers (Pack and Pluckthun, 1992), IgG constant domains (Hu et al., 1996) or Fc-regions 
(Li et al., 2000); tetravalent molecules were achieved by covalent linkage with 
homomultimers such as streptavidin (Kipriyanov et al., 1995; Kipriyanov et al., 1996; 
Cloutier et al., 2000) or the multimerization domain of p53 (Rheinnecker et al., 1996; Liu 
et al., 2007) and assessed for pretargeted immunotherapy (Schultz et al., 2000; Goshorn 
et al., 2001; Lin et al., 2006) and biotinylated drug delivery (Wang et al., 2007). 
ScFvs were also engineered into bifunctional fragments through conjugation or 
attachment to toxins (Chaudhary et al., 1989) and radionuclides (Kuan et al., 1999) mostly 
for cancer therapy,  liposomes (Laukkanen et al., 1994) and enzymes (Sharma et al., 2005) 
for improved drug delivery, quantum dots (Wang et al., 2008) for imaging, viruses 
(Nakamura et al., 2004) for gene therapy, and cytokines (Halin et al., 2002) or chemokines 
(Guo et al., 2004) for immunotherapy. 
 
1.3. From the bench to the frontline: current applications of scFvs 
 The improvement of methodologies that allow for the development of scFv 
antibodies and the advantages they present over conventional mAbs has potentiated the 
use of these fragments in very different, and sometimes complimentary, applications that 
Diabody Tetrabody Triabody Multipecific scFv Minibody 
CH CH 
A B C 
Figure 3. Multimeric formats of scFv. 
Several complexes with tailored valences and specificities can be engineered using scFvs as building blocks. Here are represented examples of several categories of multimeric scFv formats. A. Diabodies, triabodies and tetrabodies can be obtained by assembling two, three or four, respectively, scFvs, for an increase in valency. There is also the possibility of engineering these antibody formats for increased specificity (bispecific, trispecific and tetraspecific) by combining scFvs selected for different antigens. B. Multi- or bispecif scFvs combine scFvs with different antigenic targets. C. Minibody assembled by combining scFvs with two IgG’s constant domains. 
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range from research to therapeutics and in vivo imaging. The contribution of scFvs and its 
development to these areas and recent examples will be detailed below. 
 
ScFv fragments have become an increasingly useful tool in the study of protein 
functions and their molecular mechanisms, particularly when only a domain of the protein 
needs to be studied.  
RNAi technology has been used routinely for the purpose of studying protein 
function but as it down regulates the expression of the whole protein it is unhelpful when 
the aim is to focus on specific domains. Moreover, the use of this technology in vivo has 
elicited several problems regarding delivery to the target tissue and consequently off-target 
toxicity issues (Aagaard and Rossi, 2007). ScFvs, on the other hand, can be selected 
specifically for different protein domains and for different epitopes in those domains as 
was the case of a study that reported the development of scFv fragments that targeted 
different epitopes of the G-protein coupled receptor CXCR2 as allosteric antagonists and 
showed ligand-dependent differences in functional assays (Rossant et al., 2014).  
These antibody fragments are also becoming a strategic tool to study the 
importance of individual domains in the understanding of the general mechanism of action 
of a protein and its loss of function. Murphy and colleagues engineered a scFv capable of 
inhibiting the activity of MT1-MMP, a pericellular protease involved in tumour cell invasion 
and angiogenesis, by binding to a non-catalytic domain. Also this study presents a 
potential novel approach to inhibit proteinases by targeting sites outside the catalytic 
domain (Basu et al., 2012). Another study dissected the activity of Pax6, a homeodomain 
transcription factor, in the migration of oligodendrocyte precursor cells, using a scFv 
against the extracellular domain of Pax6 that lead to loss of function (Di Lullo et al., 2011). 
A plasmid carrying the scFv was electroporated in the neural tube and the scFv was able 
to neutralize the extracellular domain emphasizing its involvement in the process being 
studied.  
A recent report elucidated the role of EMMPRIN (extracellular matrix 
metalloproteinase inducer) down-regulation in the promotion of apoptosis through the 
mitochondrial pathway by intracellular acidosis via intracellular expression of a scFv using 
a chimeric adenoviral vector (Thammasit et al., 2015). This highlights another advantage 
of scFvs against RNAi technology as scFvs can be delivered by a viral vector, avoiding 
the need for multiple administrations and ensuring maintenance of antibody concentration 
to sustain silencing.  
As has been shown scFvs can be used to study protein and domain functions in 
both in vitro and in vivo studies. Moreover studies of this nature can also lead to new 
therapeutic targets and reveal molecules with therapeutic potential. 
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Therapy is perhaps the leading driver for the great improvements registered in scFv 
development, in the last few years, especially cancer therapy.  
ScFvs present several properties that are important in cancer therapy such as the 
ability to specifically recognize markers expressed in tumour cells and a reduced size for 
better and more even tissue penetration. A smaller size also means faster clearance rate 
and while that can be beneficial when scFvs are coupled with drugs or toxins, allowing for 
a lower exposure for healthy tissue, it also compromises the ability of the scFv to 
concentrate in the tumour when they’re not conjugated. As was already discussed above, 
this problem was overcome by engineering multimeric scFv complexes. 
ScFv-based tumour therapy involves targeting specific markers in cancer cells and 
neutralizing the protein, delivering a therapeutic entity such as a toxin, a drug or siRNA, or 
initiate an immune response. 
A scFv derived format that has seen great 
approval and development in the area of cancer 
immunotherapy are BiTEs (Bispecific T-cell 
Engagers) (Figure 4). Recently the first BiTE 
fragment, Blinatumomab (Amgen), was approved 
by the FDA for the treatment of refractory 
Philadelphia chromosome–negative acute 
lymphoblastic leukemia. This antibody redirects 
unstimulated primary human T cells towards 
CD19-positive lymphoma cells but presents the 
disadvantage of requiring continuous IV infusion 
due to its low molecular weight. Concurrently 
some more bispecific antibodies are now 
undergoing clinical trials, several are also BiTEs, and the group also includes tetravalent 
bispecific antibodies that should not require such a frequent administration as 
blinatumomab (Sheridan, 2015; Wu et al., 2015).  
 
Another area being developed in scFv-mediated cancer therapy are recombinant 
immunotoxins (RITs) in which scFv are used to direct cytotoxic drugs to cancer cells. This 
is achieved by replacing the cell binding domain of Pseudomonas exotoxin A with a scFv 
specific for the desired antigen (Liu et al., 2012). Several immunotoxins are currently 
undergoing clinical trials such as SSP1 which is being evaluated in combination with 
chemotherapy for treatment of malignant pleural mesothelioma (Hassan et al., 2014) and 
moxetumomab  pasudotox for advanced hairy cell leukemia (Kreitman et al., 2012) which 
is in a phase III clinical trial. At the same time more immunotoxins are being investigated 
Target cell 
T cell 
Antigen 
BiTE 
CD3 
Figure 4. BiTE. 
BiTEs are bispecific diabodies, in which one of the scFv fragments is specific for CD3, the signal transduction element of the T-cell receptor (TCR), while the other engages with a protein found at the surface of target cells. This forms a link between the target cell and the T cell which will release cytotoxic proteins, despite the absence of MHC I or co-stimulatory molecules, triggering apoptosis of the target cell. This imitates physiological events registered during T cell attacks (Wu et al., 2015). 
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as novel EGFR-specific immunotoxins using scFvs derived from already approved mAb 
therapies (panitumumab and cetuximab) (Niesen et al., 2015) . 
 
Neurodegenerative diseases have also applied scFvs to attempt to generate 
therapies which was possible because scFvs are capable of crossing the blood brain 
barrier, even when they are administered peripherally, and can be overexpressed in vivo, 
allowing for prolonged therapy without repeated injections (Robert and Wark, 2012).  
For example, in Alzheimer’s disease, anti-Aβ scFv, overexpressed via AAV 
(adeno-associated virus) delivered by intracranial injection, have been shown to reduce 
amyloid plaques in mice and were still detectable in the brain without causing neurotoxicity 
(Ryan et al., 2010). Less invasive administration routes were also studied, namely 
intramuscular (Wang et al., 2010; Yang et al., 2013) and intranasal (Cattepoel et al., 2011); 
both were successful and lead to reduction of Aβ accumulation. A more recent study 
reported scFvs that bind toxic oligomeric but not monomeric or fibrillar tau and were 
capable of detecting it in earlier stages than usual, demonstrating potential for biomarker 
development (Tian et al., 2015). Another study demonstrated the in vivo effects of a pan-
amyloid specific scFv antibody that mitigated memory deficits and brain amyloid load in 
mice with Alzheimer’ Disease (Zhao et al., 2014). 
 
In vivo imaging is another area that was has been improved by the use of scFvs 
especially regarding diagnostic applications such as tumour detection. The low molecular 
weight of scFvs allows them to be coupled to radionuclei, quantum dots and nanoparticles 
while maintaining the necessary properties for in vivo imaging. Among these properties 
are high affinity for the target, deep tissue penetration and a fast clearance rate. As such 
the scFv format provides an ideal non-invasive tool to detect and analyse the expression 
of a specific target in vivo.  
For example, a scFv fragment specific for GRP78, a protein important for cell 
proliferation and angiogenesis, was linked to quantum dots and delivered in a xenograft 
mouse model. The complex quantum dot-scFv allowed for easy visualization of the target 
in vivo. Additionally it was also able to inhibit breast tumour growth (Xu et al., 2012).  
Quantum dots were also conjugated to anti-tumour scFvs specific for the 
oncomarkers, HER1/EGFR and HER2/neu, forming self-assembling fluorescent 
complexes with the target that enabled visualization of cancer cells in vitro (Zdobnova et 
al., 2012). 
 Magnetic resonance imaging is an emerging field in the application of scFv 
fragments as it sensitivity has been shown to improve by linking scFv antibodies with 
supramagnetic iron oxide nanoparticles (SPIONs). In tumour imaging, these particles 
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provide a clearer contrast between healthy and cancer cells due to different uptake levels 
and adding scFv allows targeting of specific cells (Vigor et al., 2010).  
Another promising imaging modality that has already adopted the scFv format is 
Photoaccoustic which also employs iron oxide nanoparticles. In this case, the 
nanoparticles were conjugated with an anti-HER2 scFv and used to image HER2-positive 
tumours (Kanazaki et al., 2015). 
 
Since they were introduced, scFvs have become progressively more applicable in 
research laboratories, diagnostic and therapeutic applications. As this format of fragments 
continues to evolve and its uses become more widely acknowledged it is expected that it 
will also become more relevant in the progress of all the areas mentioned above, but more 
particularly in therapy. 
   Engineering scFv by Phage Display Technology 
  Conventionally, scFv antibodies were produced from hybridoma cells acquired 
from immunized animals by amplification of the VH and VL domains from mRNA and 
connecting them by a polylinker followed by insertion in the choice vector (Huston et al., 
1988). However, lately, this technology has been surpassed by in vitro molecular 
displaying technologies due to their adaptability to high throughput formats not to mention 
the ease of manipulation to optimize scFv properties in order to produce a pool of varied 
and highly functional antibodies (Bradbury et al., 2011). 
 Three different molecular displays from which scFv can be selected and affinity 
matured have been reported, namely phage-display (McCafferty et al., 1990), ribosome 
display (Hanes and Pluckthun, 1997) and cell surface display (Francisco et al., 1993; 
Boder and Wittrup, 1997).  All three formats share the same basic principle as molecular 
display libraries, created by cloning a diverse collection of rAb genes, are screened for 
target antigen binding and the resulting enriched pools are amplified after each round of 
selection with the target. After a few selection rounds the polyclonal pools are screened 
for antigen reactivity.  
 
2.1. Molecular Display Libraries 
 Antibody diversity results from somatic recombination in B lymphocytes through a 
combination of three different gene segments, V, D and J.  Depending on the source of 
the variable region genes, four different types of molecular display libraries can be built.  
FCUP DEVELOPING SYNTHETIC TOOLS TO IMAGE AND MODULATE THE ACTIVITY OF CHIP 9  
 
Immune libraries derive from immunoglobulin genes of lymphocytes from 
immunized animals (Clackson et al., 1991) or naturally immunized (Jacobin et al., 2002) 
or infected, humans (Burton et al., 1991). These libraries have been constructed from 
various species, besides humans, including mouse, chicken, rabbit and camel 
(Hoogenboom et al., 1998). Despite being antigen-specific and enriched in affinity matured 
clones they also present several disadvantages such as the need to create a new library 
for each antigen, the time required for immunizations and the unpredictability of the 
immune response (Azzazy and Highsmith, 2002).  
 
Naïve, synthetic and semi-synthetic libraries are ‘single pot’ repertories, resulting 
from non-immunized donors and are antigen independent, consequently they represent a 
source of antibodies against a diverse assortment of antigens including self, toxic and non-
immunogenic antigens (Marks et al., 1991; Griffiths et al., 1993; Vaughan et al., 1996).  
Naïve libraries offer the possibility to select antibodies of desired specificity and 
high affinity without immunization being necessary (Burton et al., 1991). Genes 
responsible for the variable domain are obtained through B-cell mRNA amplification using 
oligonucleotides specific for the VL and VH families. The heavy and light chains are then 
randomly combined and cloned to create a combinatorial scFv library. This procedure 
gives access to germline antibodies, this is, antibodies that have yet to be exposed to 
antigens, however the frequency of those antibodies is dependent on the source of the B-
cells (Marks et al., 1991). 
 Synthetic libraries result from in vitro assembly of V, D and J gene segments.  
Assembly of V-genes artificially allows for introduction of diversity using PCR techniques 
and degenerate primers to randomize CDR regions (Hoogenboom and Winter, 1992). The 
heavy chain CDR3 has been the main target of these modifications in synthetic repertoires.  
Examples of synthetic libraries include the Tomlinson I and J libraries (de Wildt et al., 2000; 
Goletz et al., 2002) and the human combinatorial antibody libraries (HuCAL) for scFv 
(HuCAL-scFv) (Knappik et al., 2000) and Fab fragments (HuCAL-Fab1, HuCAL GOLD, 
HuCAL PLATINUM) (Rauchenberger et al., 2003; Rothe et al., 2008; Prassler et al., 2011) 
Semi-synthetic libraries combine elements of both natural and synthetic origin in 
order to increase natural diversity while introducing synthetic functional diversity. These 
libraries are typically created by amplifying natural naïve CDR1 and CD2 regions and 
synthetically randomizing CD3 regions, by shuffling natural CDR regions or by 
combinatorial mutation of certain amino acids in the VH and VL chains of the CDR3 region 
(Barbas et al., 1992). It has also been reported a synthetic library that combined synthetic 
CDR1 and CDR2 regions and a natural CDR3 (Hoet et al., 2005). 
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All these three libraries are amenable to high throughput screening and capable of 
generating and selecting thousands of antibodies specific to different epitopes on the same 
target. 
 
2.2. Phage Display 
 Phage-display is the oldest and most frequently used system for molecular display. 
This technique was first implemented in 1985, when Smith and colleagues showed that 
foreign DNA fragments could be fused to the gene encoding the phage minor coat protein, 
pIII, of a nonlytic filamentous bacteriophage and consequently expressed in the form of a 
fusion protein at the surface of the phage without affecting the its infectivity (Smith, 1985). 
Later, a team of researchers based in Cambridge successfully applied this technology to 
the production of scFv antibodies by showing that these fragments could be displayed at 
the surface of the virion as functional proteins capable of binding to antigens (McCafferty 
et al., 1990). 
The phage of choice is M13, a flexible rod like shaped filamentous phage with a 
6000 to 8000 bases circular genome surrounded by a coat of five different proteins. One 
end of the phage displays by five copies of each of the two minor coat proteins, pIII and 
pVI while the other end presents three to five copies of pVII and pIX; the rest of the phage 
particle is covered with several thousand copies of the coat protein pVIII. (Smith and 
Petrenko, 1997).  
The most commonly used coat proteins for phage display are pIII and pVIII. The 
pIII protein is involved in phage-host interactions during infection and is 460 amino acids 
long while pVIII protein has only 50 amino acids (Crissman and Smith, 1984; Smith, 1985). 
As these proteins have an important role in viral packaging and infectivity displaying large 
foreign peptides on every copy of selected coat protein could interfere with these functions 
limiting the performance of the phage display technology.  
This obstacle could be overcome by expressing the foreign fragment only in a 
portion of the coat protein and different solutions were engineered to achieve this goal. In 
some phage display systems instead of introducing the DNA encoding the scFv library 
directly into the phage genome, the library is inserted as a gene cassette encoding scFv-
pIII fusion proteins. This way the phage will retain the wild type pIII protein copy ensuring 
that only some pIII coat proteins display scFvs (Smith and Petrenko, 1997).  
Another option is to insert the fusion coat protein in a phagemid (a plasmid with 
both phage and E. coli derived origins of replication), while the WT coat protein and the 
remaining genes essential for phage assembly are delivered by a helper phage with a 
deficient packaging signal. Co-infection of the bacteria by the phagemid and the helper 
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phage produces hybrid virions with the phagemid genome and displaying only limited 
copies of the fusion coat protein (Vieira and Messing, 1987; Mead and Kemper, 1988). 
During phage assembly WT pIII competes with the fusion protein for integration into the 
phage particle however since in a wild type phage there is only three to five copies of pIII 
coat protein, the majority of phagemid particles will only display zero or one copy of the 
fusion protein per phage. This is the reason why higher affinity antibodies are more often 
selected from phagemid than phage libraries, as there is no avidity (O'Connell et al., 2002). 
 
The selection of scFv from phage display libraries is achieved by multiple rounds 
of probing against the desired antigen interspaced with washing steps to remove 
nonspecific phage clones. Typically, several rounds of panning with progressively 
increased washing stringency in between are performed to enrich the resulting phage 
pools with the highest affinity binders (Figure 5). This process is denominated biopanning 
and it is generally performed against a target immobilized onto a solid support as microtiter 
plate wells (Schofield et al., 2007), immunotubes (Weisser et al., 2007) or columns 
(McWhirter et al., 2006). Additionally, the phage library can be incubated with biotinylated 
antigen and then the antigen-phage complex is captured using a streptavidin surface 
(Winter et al., 1994). This approach could be beneficial for proteins that suffer 
conformational changes due to immobilization or so as not to limit the epitopes exposed 
to the panning.  
In order to retrieve the phage particles that express scFv fragments capable of 
binding to the target protein an elution step is performed. Several elution strategies have 
been used including low (Smith, 1985) or high (Parmley and Smith, 1988) pH buffers, 
proteolytic cleavage (Ward et al., 1996), competition with free antigen (Oldenburg et al., 
1992) and even ultrasound (Lunder et al., 2008).  
The eluted phages retain their infective capacity and can therefore be propagated 
by infecting new bacterial hosts, to yield an amplified library, already more specific for the 
target protein, that can serve as input for the next affinity panning round. Usually only two 
to three rounds of panning are necessary however this can vary depending on the target 
protein. The eluate from the final round of panning are propagated and subjected to further 
analysis to isolate clones of interest. 
Phage display of scFvs presents several advantages over other techniques. High 
stability of the phages allows storage at 4ºC for several years (Burritt et al., 1996) and 
makes phage display amenable to obtain binders for a specific conformation, structure, 
folding or enzymatic activity of the target protein (Forrer et al., 1999). Additionally, scFv 
production can be achieved swiftly and economically just by infecting E.coli. 
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Recent improvements in this technique include the development of a high-
throughput phage-display screening in array format using a protein chip carrying 
recombinant phage particles that aims to facilitate antibody identification and 
characterization (Diez et al., 2015); an industrialized platform to generate high affinity 
antibodies for transcription factors and epigenetic antigens through an optimized 
automated phage display and antigen expression pipeline capable of producing a great 
number of sequenced Fabs with high affinity stability and good expression in E. coli 
(Hornsby et al., 2015); and generation of scFv fragments capable of revealing structural 
differences of amyloid-β fibrils resulting from variations in the acidity of the environment 
during the fibrillogenesis process (Droste et al., 2015).  
In summary, phage display technology has seen great improvements since it was 
first developed in 1985 in order to accommodate the new applications and demands of 
today’s science. This technique has been particularly useful in the high throughput 
development of new scFv fragments which in turn have been widely used in basic research 
Figure 5. Phage Display Cycle. 
A library of gene variants of antibody fragments (A) is expressed on the surface of M13 phage (B) and incubated with an immobilized antigen to select based on the expressed epitopes antigen binding scFv (1). After extensive washing to removeunbound and low affinity phage particles (2), the remaining bound phage particles are eluted (3). The selected phage are used to infect host cells (4) which are then grown (5) originating a “new” library enriched with variants of antibody fragments capable of high affinity interaction with the desired antigen (polyclonal pool). This cycle is usually repeated from two or threetimes to increase the pool of high affinity antibodies. The use of phage display results in selection of high affinity antibodies, that can be expressed and characterized (C) (Smith, 1985). 
A. scFv genes 
Repeat 2-3 times 
B. Phage Library 
2. Washing 
3. Elution 
4. Infection 
5. Amplification  
Host  cells 
C. Characterization 
1. Selection 
FCUP DEVELOPING SYNTHETIC TOOLS TO IMAGE AND MODULATE THE ACTIVITY OF CHIP 13  
 
and immunotherapy, as has been described before. Considering the evolution this 
technique has achieved and seeing as it is still extensively employed, new developments 
are to be expected and new applications unveiled. 
 2.3. Alternative Molecular Display Systems 
 Even though phage display is the most commonly used molecular display system, 
Ribosome and Cell Surface display also have to be considered as two well-established 
techniques which also have their advantages. 
 
 Ribosome display doesn’t require cell growth or transformation as it is a fully in 
vitro transcription/translation system. The concept involves the translation of the scFv 
encoding nucleic acids to form a complex that is then incubated with the target protein to 
select specific binders (Figure 6). This system can overcome the limitations of cell-based 
displays such as the expression bias and generate larger libraries than phage or cell 
surface display constituting a powerful alternative to the remaining molecular display 
systems (Hanes and Pluckthun, 1997). 
 
 
  
  
 
 
 
 
In the cell surface display system, thousands of copies of the scFv are anchored 
to proteins such as the Lpp-OmpA chimera on the membrane of E.coli (Francisco et al., 
1993) or the α-agglutinin adhesion receptor on the cell wall of yeast (Boder and Wittrup, 
1997) and consequently displayed on the surface of the cells and selected with 
Fluorescent Activated Cell Sorting (FACS) technology. This selection technique allows for 
Figure 6. Alternative Molecular Display Systems. 
A. Ribosome Display. mRNA molecules are incubated with a stoichiometric amount of ribosome and once the translated antibody fragment emerges from the ribosome, the lack the stop codons will lead to the formation of a protein-ribosome-mRNA complex. The presence of a spacer region at the 3’ terminal of the DNA library ensures the fusion to the ribosomewhile allowing the protein to fold correctly. The complexes are then incubated with the immobilized target to probe for binding. Elution is achieved by destruction of the complex or competitive elution with free ligands. The eluted mRNA is subjected to reverse transcription-PCR in order to obtain DNA for the next round of panning (Hanes and Pluckthun, 1997). B. Cell Surface Display. The protein of interest is expressed at the surface of the cell fused with one of its surface proteins and high-affinity binders can be selected and quantified, according to scFv expression and antigen binding, by flow cytometry using both fluorescently labelled antigens and anti-epitope tagged reagents (Boder and Wittrup, 1997). 
scFv 
Cell Surface Display Ribosome Display 
scFv 
Nucleic acid Spacer 
A B 
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a swift and quantitative screening and ensures that tightly bound clones will be recovered. 
The most popular format is yeast display but E. coli and Bacillus thuringiensis (Du et al., 
2005). 
   CHIPping Away at the Unknown 
 The Carboxy-terminus of Hsc-70 Interacting Protein (CHIP) is a 35kDa 
homodimeric quality control E3 ligase. CHIP is highly expressed in tissues with high 
metabolic rates such as the heart, the adult striated muscle and the brain. Intracellularly, 
it is known for being present in both the cytoplasm (Ballinger et al., 1999) and the nucleus 
under different conditions (Meacham et al., 2001) 
Evolutionarily, CHIP’s amino acid sequence is well-conserved across several 
species, sharing a particularly high similarity with that of mouse (~98%) and its 
ubiquitination domain, the U-box, is the least altered region of the sequence. This protein 
was first described in 1999 when it was discovered during an assay that aimed to identify 
TPR-containing proteins in the heart by screening a phage library of human heart cDNA 
against a fragment of cytochrome 40 (Ballinger et al., 1999).  
Fifteen years later, even though several CHIP interactors and substrates have 
been identified and its relevance in physiology and disease has been widely studied, little 
is still known about its molecular mechanistics and regulation.  
 
3.1. Unravelling CHIP’s Structure and Activity 
 
The maintenance of normal cellular functions rests heavily on the integrity of the 
cell’s proteome; to this end, the cell possesses a set of pathways responsible for 
monitoring and maintaining the health of its proteins. Central to these pathways are the 
molecular chaperones that can promote the folding of misfolded protein, and if that’s not 
possible target them to the ubiquitin-proteasome system (UPS) which is responsible for 
the degradation of proteins usually marked with ubiquitin tags.  
The addition of ubiquitin to the target proteins is accomplish through a process 
known as ubiquitination, which requires a succession of biochemical reactions catalysed 
by three different groups of enzymes (Figure 7). CHIP belongs to the group of the E3 
ubiquitin ligases.  
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In fact, CHIP plays an important role in the ubiquitin-proteasome scheme as a 
bridge between the molecular chaperone system and the degradation pathway due to its 
functions as both a quality control E3 ubiquitin ligase and a co-chaperone of several heat 
shock proteins (Hsp) (McDonough and Patterson, 2003).  
 
CHIP’s structure is intimately associated with its activity. Each monomer (34.5kDa) 
displays two specialized domains, which impact CHIP’s activity in a different but 
complementary manner, joined by a central coiled-coil region. The amino terminus 
contains three tetratricopeptide repeats (TPR), responsible for the interactions with 
chaperones, and the carboxyl terminus displays a U-box domain that grants CHIP its E3 
ubiquitin ligase activity (Figure 8) (Zhang et al., 2005). 
 
 The U-box, positioned at the C-terminus, is structurally similar to RING finger 
domains, the main difference resting on the fact that U-boxes are stabilized by hydrogen 
bonds instead of zinc binding (Aravind and Koonin, 2000). CHIP’s U-box (residues 232-
298) contains a pair of β-hairpins running into a short α-helix followed by a third hairpin 
and concluding in in a C-terminal α-helix (Zhang et al., 2005). This region acts as a scaffold 
or an adaptor, positioning the substrate in proximity with the E2-ubiquitin complex, as 
opposed to the HECT ubiquitin ligases, that form transient thioester links with the ubiquitin 
molecule and transfer it to the substrate (Passmore and Barford, 2004). 
 
 The TPR domain (residues 26-131) includes three TPRs, each of which consists 
of two antiparallel α-helices separated by a turn to form a ‘knob and hole’ structure (Zhang 
et al., 2005) with a hydrophobic surface that facilitates protein:protein interactions (Das et 
al., 1998). This domain is primarily responsible for CHIP’s interactions with the Hsc/Hsp 
proteins.  
Initially it was believed that TPR domains were mostly rigid, invariable structures, 
even upon ligand binding. Nevertheless recent structural and dynamic studies have 
suggested otherwise and added that binding to the TPR domain can actually lead to large 
conformation changes in the protein as a whole (Parashar et al., 2013). 
This possibility has already started to be investigated for CHIP. A study conducted 
using Hydrogen/Deuterium Exchange coupled with Mass Spectrometry (HDX-MS) 
demonstrated that the TPR domain in CHIP is not only loosely folded but also that the first 
sixty amino acids are intrinsically disordered. Also it was revealed a high degree of 
flexibility in the TPR domain which decreased upon Hsp70 or Hsp70 peptide binding (Graf 
et al., 2010).  
FCUP DEVELOPING SYNTHETIC TOOLS TO IMAGE AND MODULATE THE ACTIVITY OF CHIP 17  
 
These results above were supported by a recent publication that additionally looked 
at a CHIP TPR mutant (CHIP-K30A), in which the lysine in position 30 was replaced by an 
alanine, a residue that encourages helix formation. This protein had only been studied as 
a non-chaperone binding mutant of CHIP with decreased catalytic activity. However it was 
revealed that, when compared with wild type CHIP, the mutant presents a TPR domain 
with reduced flexibility, equivalent to the decrease seen for the ligand-bound TPR domain. 
Additionally molecular dynamics studies were conducted and it was shown that the 
mutation affected not only TPR movements but also the U-box’s. This observation lead 
the way to a new mechanism of regulation for CHIP and established the K30A mutant as 
a useful tool to study the effect of TPR stabilization in the absence of a ligand (Narayan et 
al., 2015).  
 
 
The TPR and the U-box domains are brought together by a charged coiled-coil 
domain (helix 7 and 8), essential for the coupling of CHIP’s inactive monomers and 
consequently its function. as enzymatic activity of CHIP is dependent on its dimerization 
(Nikolay et al., 2004). When CHIP dimerizes, the two protomers adopt significantly 
different conformations forming an asymmetric dimer. The assembly of CHIP’s two 
monomers involves the interaction of the U-box domain and the central helical domain of 
Figure 8. Representation of CHIP’s structure. 
(A) Structure of the CHIP protomer that presents the ‘broken’ coiled coil domain (CC) indicating the tetratricopeptide repeatdomain (TPR) and the U-box domain. (B) As in (A) but for the protomer that maintains a straight coiled coil domain. (C) The two protomer assembled. These images were obtained from PDB file 2C2L (Zhang et al., 2005) using the graphic software Visual Molecular Dynamics (VMD) (Humphrey et al., 1996) coloured according to the different secondary structure motifs present. 
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each monomer. However helix 7 adopts distinct conformations in the two monomers; in 
one remains a straight α-helix while in the other it breaks forming two perpendicular α-
helices. This, along with a dislocation in the U-boxes and the helical domains symmetry 
axes leads to structural arrangements that positions the TPR domain of one of the 
protomers in front of its U-box domain, blocking it. For this reason CHIP displays a “half-
of-sites” activity (Zhang et al., 2005).  
 
CHIP is predominantly responsible for the ubiquitination of chaperone-bound 
substrates by binding to C-terminal of Hsp/c70 and Hsp 90 with its TPR domain in order 
to facilitate ubiquitination via its catalytic U-box by the 26S proteasome. Chaperone clients 
usually include chaperone activated signalling proteins and proteins prone to aggregation 
that are subjected to chaperone assisted quality control (Connell et al., 2001; Jiang et al., 
2001). 
In order to perform its role as ubiquitin ligase, CHIP depends on the interaction with 
E2 proteins. CHIP has been shown to interact with UbcH5 to produce Lys-48-linked 
polyubiquitination and with E2 complex Ubc13-Uev1A to generate Lys-63-linked 
polyubiquitination. This suggests the product formed in CHIP-mediated ubiquitination 
reactions is dependent on which E2 is involved (Xu et al., 2008). Another study identified 
a set of other seven other E2 enzymes that bind and function with CHIP in vitro to produce 
all types of ubiquitination events. This study also confirmed that CHIP requires the SPA 
motif in loop 7 of E2 for recognition and binding (Soss et al., 2011).  Different ubiquitination 
patterns have also been described depending on the E2 present but also due to small 
changes in the substrate, as ubiquitination assays showed that the distribution of multiple 
ubiquitination chain types is different for Hsp70 versus Hsc70, even though these proteins 
present highly sequence homology and similar structure (Soss et al., 2015). 
Additionally, CHIP has also been shown to interact with other E3 ligases to facilitate 
their ubiquitination activity, functioning as an E4 ligase. So far this function of CHIP has 
been demonstrated for Parkin, considered the culprit for a juvenile form of Parkinson (Imai 
et al., 2002), and for the complex SCFSkp2 (Nie et al., 2008). 
 
3.2. Regulation 
 CHIP is regulated at different levels and new insights about possible mechanisms 
have been in study lately. 
Few studies have been dedicated to studying CHIP’s transcriptional regulation 
under physiological and pathological contexts. Still, it is to be expected that in case of a 
massive accumulation of misfolded proteins, quick adjustments of the levels of Hsp70 
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chaperones and its co chaperones would be required so as to maintain homeostasis. The 
levels of CHIP and/or Hsp70 mRNA are in fact upregulated and have, in vivo and in vitro, 
protective effect under stress conditions such as heat shock, pathological polyQ 
overexpression (Miller et al., 2005; Dikshit and Jana, 2007) and oxidative stress 
(Stankowski et al., 2011). A decrease in CHIP’s mRNA and protein levels has been 
observed in breast cancer (Kajiro et al., 2009; Patani et al., 2010), colorectal (Ruckova et 
al., 2012; Wang et al., 2014b) and gastric cancer (Gan et al., 2012) and correlated greatly 
with prognosis. These results are in agreement with evidence showing that CHIP acts as 
tumoral suppressor. 
The one example of CHIP posttranscriptional regulation that has been reported so 
far is in the context of bone morphogenesis as translational repression of CHIP by miR-
764-5p was deemed essential for adequate osteoblast differentiation (Guo et al., 2012). 
Posttranslational modifications (PTM) of CHIP have also been investigated 
however only ubiquitin modifications have been reported. CHIP undergoes a regulatory 
ubiquitination in cells and in vitro which doesn’t promote its turnover but instead facilitates 
substrate targeting for proteasomal degradation (Jiang et al., 2001; McDonough and 
Patterson, 2003). For instance, Ataxin 3, an ubiquitin-interacting motif containing 
deubiquitinase, provides chain editing activity for CHIP by binding and deubiquitinating 
CHIP upon completion of substrate ubiquitination however this activity is dependent on E2 
Ube2w ubiquitination of CHIP (Scaglione et al., 2011).  Additionally it has also been 
reported that CHIP undergoes extensive autoubiquitination however the extension of this 
process seems to be dependent on the E2 enzyme present in the reaction (Soss et al., 
2011; Soss et al., 2015). Until recently no direct evidence of other PTMs had been found. 
It had only been proposed that CHIP had functional phosphorylation sites (Dephoure et 
al., 2008) and interacted with protein kinases such as ERK5 and Lim Kinase 1 (LIMK1) 
(Lim et al., 2007; Woo et al., 2010). However recently a study reporter that Cdk5 
phosphorylates CHIP at Ser20, promoting tAIF-mediated neuronal death (Kim et al., 
2015). 
Moreover substrate PTM and conformation changes also have roles in functional 
regulation of CHIP. For instance, under stress conditions, Abl phosphorylation of MST1 
kinase inhibits its degradation by CHIP allowing it to bind to FOXO3 and trigger neuronal 
cell death (Xiao et al., 2011). Also Landré and colleagues reported that IRF-1 (interferon 
regulatory factor-1) ubiquitination by CHIP was inhibited when IRF-1 adopted a DNA 
bound conformation as it obstructed the E3 docking site (Landre et al., 2013). 
The activity of CHIP is also regulated by its interactions with other proteins. This 
regulation occurs by varied mechanisms including: competition with substrate binding (eg. 
S100 proteins) (Shimamoto et al., 2013); competition with chaperone binding (eg. Xap2) 
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(Lees et al., 2003); conformational modification of the chaperone complex (eg.HspBP1) 
(Alberti et al., 2004); interference with CHIP:E2 interaction (eg. BAG2) (Arndt et al., 2005); 
facilitation of chaperone binding (eg. BAG1/3) (Demand et al., 2001; Dai et al., 2005) and 
of the interaction with the E2 (eg. S5a) (Kim et al., 2009). 
It has also been proposed a chaperone-mediated allosteric model of CHIP 
regulation. An in vitro study, carried out using wild type and a U-box mutant (P269A) CHIP 
without E3 ligase activity, suggested that CHIP-Hsc70 binding is dependent on allosteric 
interactions between the U-box and the TPR domains. The increased binding efficiency of 
TPR to Hsc70 by the U-box mutation raised the possibility that the U-box contributes to 
TPR domain folding, induced during binding to Hsc70 (Matsumura et al., 2013). In line with 
this allosteric model, recent publication reported that changes in the TPR domain flexibility, 
secondary structure and motion also impact the U-box, as a TPR mutant with a less flexible 
conformation also showed decreased catalytic activity. Furthermore this study suggested 
that Hsp70 can modulate CHIP’s ubiquitination activity on native proteins, through the TPR 
domain, on top of its function as a targeting signal for CHIP in the chaperones and protein 
control pathways (Narayan et al., 2015). 
 
3.3. Two ends of the same CHIP: physiology and disease 
 In view of CHIP’s position as hub between the ubiquitin/proteasome system and 
the chaperones’ pathway it is not difficult to conceive its involvement in numerous cellular 
processes and the important role it presents in the regulation of a great number of proteins. 
Thus CHIP’s significance in several physiological and disease related processes has been 
avidly studied. 
 
Currently, CHIP is well established as an E3 ubiquitin ligase and as such, one of 
its main physiological functions is to ensure the maintenance of protein quality under both 
normal and stress situations. Denatured proteins or nascent polypeptides are recognized 
by chaperones, due to their exposed hydrophobic surfaces, and failure to refold them 
triggers degradation. As CHIP associates closely with chaperones it gains access to a 
whole portfolio of clients. 
Several publications have linked CHIP to the ER associated degradation pathway 
(ERAD). First it was shown that CHIP was necessary for proper biogenesis of CFTR 
(Cystic fibrosis transmembrane conductance regulator) as it promoted degradation of 
misfolded receptors. Consequently CHIP became a possible target for strategies that aim 
to rescue misfolded but potentially functional receptors from ERAD without affecting pro-
folding activities (Matsumura et al., 2013). Then Donelly and co-workers identified CHIP 
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as a promoter for HSP70/90/40 mediated ER degradation of the NaCl cotransporter (NCC) 
which due to its complex topology is not processed efficiently and is prone to suffer ERAD 
(Donnelly et al., 2013). More recently CHIP was reported as an E3 ligase for nicotinic 
acetylcholine receptor α3 subunit and UBXN2A was identified as an adaptor protein that 
may efficiently regulate the stability of CHIP's client substrates, by interfering with CHIP-
mediated ERAD (Teng et al., 2015). Another report showed that CHIP overexpression 
prevented cell death, by pharmacologically induced RE stress in the hippocampus, and 
up-regulation p53 pro-apoptotic pathways (Cabral Miranda et al., 2014). 
Besides its role in ubiquitinating misfolded substrates, CHIP has also been reported 
to interact with non-native and denatured proteins under conditions of stress (eg. heat) in 
an Hsp70 independent manner, in order to fold them. The molecular mechanism for this 
multifaceted role for CHIP is not completely understood but it has been suggested it can 
be due to conformational changes and oligomerization status (Rosser et al., 2007). 
CHIP was also implicated in oxidative stress when it was reported that exogenous 
overexpression of CHIP in HT-22 cells in acute oxidative stress conditions impaired 
neuronal survival and led to a loss of proteasome activity; curiously an overload of 
polyubiquitinated proteins was offered as a cause for proteasome impairment (Stankowski 
et al., 2011). In a more recent study, CHIP exhibited Hsp70 dependent interaction and 
degradation of endonuclease G under normal but not in oxidative induced stress 
conditions. This reveals a new CHIP mediated protective mechanism against oxidative 
stress (Lee et al., 2013). 
Additionally, CHIP has recently been suggested as a regulator of the autophagic 
flux as CHIP knockdown induced autophagosome formation due to an increase in the 
levels of PTEN and decreased AKT/mTOR activity (Guo et al., 2015) 
 
Apart from its roles in mediating protein quality control under stress situations, 
CHIP is involved in the regulation of the Base Excision Repair (BER) pathway, responsible 
for processing simple lesions in DNA, by catalysing the ubiquitination of proteins that are 
not bound in repair complexes (Parsons et al., 2008). It also plays a role in the maturation 
of aggresomes, inclusion bodies rich in ubiquitin where misfolded proteins are sequestered 
(Sha et al., 2009) 
 
As every coin has two sides, once CHIP’s functions and participation in 
physiological pathways came to light, it also became evident its possible influence in 
several disorders and pathologic processes. 
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  One of the earliest examples of CHIP’s role in human disease was reported in 
publications regarding Parkinson’s disease, a neurodegenerative aggregation pathology. 
The first study focused on the involvement of CHIP in potentiating Parkin mediated 
ubiquitination of Pael-R, a receptor that accumulates in Lewy bodies which are a hallmark 
of Parkinson’s disease. CHIP mediates the displacement of Parkin/Pael-R from Hsp70 
allowing Parkin to ubiquitinate Pael-R (Imai et al., 2002).  
Nowadays, CHIP related research in this area is focusing more on α-synuclein as 
it has been found that CHIP co-localizes with this intrinsically disordered protein and Hsp70 
in Lewy bodies-like inclusions and decreases in vitro formation of inclusions in a model of 
α-synuclein aggregation. Besides, it was also suggested that CHIP was capable of 
promoting α-synuclein degradation via proteasome, by a TPR dependent mechanism, or 
through a U-box dependent lysosomal pathway. Additionally it has been shown CHIP’s 
ability to selectively reduce the toxicity of α-synuclein stabilized oligomeric forms while 
having no effect on cytotoxic manifestations resulting from more transitory interactions of 
α-synuclein (Shin et al., 2005; Tetzlaff et al., 2008). More recently it was also demonstrated 
that CHIP can facilitate in vivo degradation of α-synuclein aggregates (Dimant et al., 2014).  
CHIP has also been implicated in the ubiquitination and proteasomal degradation 
of LRRK2 (leucine-rich repeat kinase 2 gene), whose mutated form is the most common 
cause of familiar Parkinson’s. This process can mitigated by Hsp90 (Ding and Goldberg, 
2009). 
 
Alzheimer’s Disease (AD) is another neurodegenerative aggregation disorder with 
which CHIP has been associated. So far, deposition of extracellular amyloid beta (Aβ) and 
hyperphosphorylation of Tau protein are the strongest causal hypothesis for the 
development of this disease. CHIP is able to target proteosomal degradation of Tau 
through an Hsc70 dependent mechanism (Shimura et al., 2004) and then it was reported 
that CHIP up-regulation attenuated tau aggregation in vivo (Sahara et al., 2005). Later, 
CHIP complexed with Hsp90 was shown to distinguish and selectively degrade 
phosphorylated tau proteins (Dickey et al., 2007) while Zhang described CHIP’s ability to 
degrade tau independently of its phosphorylation status (Zhang et al., 2008). 
Another study highlighted a critical role for CHIP as new potential target in 
tauopathies as it showed that while Aβ accumulation decreases CHIP expression and 
increases tau levels, blocking Aβ accumulation restored CHIP levels, delaying the onset 
and development of tau pathology (Oddo et al., 2008). Interestingly, a more recent study 
portrayed CHIP as a suppressor of APP cleavage into Aβ, through ubiquitination of the 
responsible enzyme, β-secretase, which is activated by p53 inactivation. However, CHIP 
is also capable of stabilizing p53's DNA-binding conformation to inhibit its interaction with 
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β-secretase promoter thus regulating β-secretase levels both transcriptionally and at a 
post-translational level (Singh and Pati, 2015). Both these mechanisms suggest CHIP as 
a possible therapeutic target in AD. 
 
The above mentioned are two of the most studied disorders nowadays however 
CHIP has also been found to participate in several other neurological disorders such as 
Huntington’s disease, spino-cerebellar ataxia-1 and spinal and bulbar muscular atrophy 
by mediating ubiquitination and supressing aggregation of polyglutamine proteins 
including huntingtin, ataxin 1 and the androgen receptor (Miller et al., 2005; Al-Ramahi et 
al., 2006; Adachi et al., 2007); Inclusively it has been reported a new CHIP-mutant related 
ataxia (Casarejos et al., 2014). CHIP has also been implicated in ALS (Choi et al., 2004; 
Urushitani et al., 2004) and Lafora Disease (Rao et al., 2010).  
 
Cancer is another pathology where CHIP seems to have an important role however 
it is not a direct one, considering contradictory concepts have been found. 
Some evidence supports CHIP’s involvement as a tumour suppressor as its levels 
have been shown to correlate negatively with tumour growth, metastasis (Kajiro et al., 
2009), migration , angiogenesis (Wang et al., 2013; Sun et al., 2015) and increasing 
malignant grades (Patani et al., 2010). More recent work proposed CHIP’s promoter 
hypermethylation as an underlying mechanism for CHIP’s downregulation in various 
cancers (Gan et al., 2012). In addition, CHIP has been associated with decreased levels 
of several well-studied oncogenic proteins such as pAkt (Su et al., 2013), c-myc (Paul et 
al., 2013), HIF-1 (Bento et al., 2010; Ferreira et al., 2013) and EGFR (Wang et al., 2014a) 
in various cancers and a few more in breast cancer particularly, including histone 
acyltransferase SRC-3 (Kajiro et al., 2009), TNF receptor interactor TRAF2 and NF-κB 
(Jang et al., 2011), differentiation regulator PTK6 (Protein-Tyrosine Kinase 6)  (Kang et 
al., 2012) and inflammatory cytokine MIF (macrophage inhibitory factor) (Schulz et al., 
2012).  
However it seems that for every study suggesting CHIP’s tumour suppression 
influence there is evidence suggesting its oncogenic properties. CHIP-mediated 
ubiquitination and degradation of tumour suppressors such as FoxO1 in response to TNF 
signalling (Li et al., 2009), and of PTEN have been reported (Ahmed et al., 2012).  
Inclusively, a tissue microarray approach detected increased expression of CHIP in 
metastatic lymph nodes of oesophageal squamous cell carcinoma (Wen et al., 2013). 
Considering cancers’ diversity and sophistication along with CHIP’s wide net of 
interactors and seemingly tight regulation it should not be a surprise if future studies find 
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this E3 ligase can in fact take on both the above mentioned roles, under different 
conditions. 
 
It is likely that as the knowledge on CHIP’s functions and mechanisms are further 
elucidated and research on physiologic and human disease pathways progresses, novel 
interactors and substrates for CHIP are revealed. In fact very recently a new study 
identified CHIP as an interactor of cellular prion protein, however physiological and 
pathologic implications of this finding are still being studied (Gimenez et al., 2015). 
 
 
3.4. Targeting CHIP  
 The physiological significance of CHIP was definitely established when it was 
demonstrated that approximately 20% of CHIP null mice (CHIP-/-) died at embryonic 
stages and the remaining were incapable of surviving thermal stress (Dai et al., 2003).  
 Since then, and as it was described previously, CHIP’s vital role in the regulation 
of varied biochemical phenomena, as well as CHIP’s own regulation mechanisms, have 
been further elucidated. CHIP’s physiological functions and its role in neurological 
disorders and cancer present this protein as a possible target for therapies; in most of 
these cases increase of CHIP’s levels or activity can lead to a favourable outcome (Ishigaki 
et al., 2007; Cabral Miranda et al., 2014). Combinatory therapeutic strategies involving not 
only CHIP but also its interactors, like chaperones, might also prove to be useful when 
both parties are involved as occurs in several pathologies (Pratt et al., 2015). 
 As CHIP’s intrinsic mechanistics, regulation and importance in disease continues 
to be investigated, new information will undoubtedly clear the way for modulation of its 
activity in order to better potentiate its aptitude as a therapeutic target. 
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II. AIM 
 
Current knowledge of CHIP has drawn the image of a highly complex protein, 
apparently tightly regulated and involved in a plethora of cell processes, often seemingly 
inconsistent however it is clear that a lot is still left to be known.  
 
The main aim of the present study was to develop and characterize single chain 
fragment variable antibodies (scFv) against the C-terminus of the Hsc70-Interacting 
protein (CHIP) by phage display technology with the long term goal of using them to image 
and modulate CHIP’s activity.  
 
The aim of the study will be achieved by the following approaches: 
 
1. Production and Purification of His-tagged wild type CHIP; 
2. Screening of a canine Phage scFv antibody library Phage Display Technology 
using His-tagged wild type CHIP and an untagged CHIP TPR mutant (K30A); 
3. Selection and validation of scFv fragments that present the highest affinity for 
the targets used (WT CHIP and CHIP K30A); 
4. Soluble expression and purification of the selected scFvs from E.coli; 
5. Characterization of the purified scFvs using sequence analysis, high-
throughput peptide and protein binding assays and gel electrophoresis 
techniques. 
6. Establishment of an in vitro interaction assay between CHIP and its known 
substrate α-synuclein;  
7. Determination of the influence of the obtained scFvs in the activity of CHIP 
using the aforementioned assay. 
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III. MATERIAL AND METHODS 
 
1. Material 
 1.1. Proteins and Reaction kits 
 The following proteins, used in this study, were kindly offered by various members 
of the laboratory: CHIP mutant K30A and untagged WT CHIP (Jia Ning), p53 (Maria Gil) 
and α-synuclein (Jonas Gasparavičius). The E2 UbeH5α used in ubiquitination assays was 
produced in the laboratory by Fiona Lickiss. His6-Ubiquitin E1 Enzyme (Ube1) and 
Ubiquitin were from Boston Biochem. Wild type His-tagged CHIP was produced and 
purified according to the protocol described in the ‘Methods’ section of this thesis. The kit 
QIAprep Spin Miniprep kit (QIAGEN) was used to isolate plasmid-DNA from E.coli. 
 
1.2. Antibodies, Conjugates and Substrates 
 All the antibodies and conjugates used in this study, as well as their provenience 
are described in table 1. 
Target Class Name Provenience 
CHIP Mouse Monoclonal 3.1 Gifted by B. Vojtesek 
α-Synuclein Mouse Monoclonal Purified Mouse Anti-α-Synuclein BD Biosciences 
p53 Mouse Monoclonal DO1 Gifted by B. Vojtesek 
M13 Phage Monoclonal Mouse Anti-M13 Phage/HRP GE Healthcare 
Mouse Immunoglobulins Polyclonal Rabbit Anti-Mouse Immunoglobulins/HRP Dako 
scFv - Protein A, HRP conjugate Millipore 
Table 1. Antibodies and conjugates. 
 
 ECL solutions I (100 mM Tris pH 8.5; 2.5 mM Luminol; 0.4 mM p-Coumaric acid; 
millipore water) and II (100 mM Tris pH 8.5; 0.02% (V/V) hydrogen peroxide; millipore 
water) used as a substrate for Western blotting and enzyme-linked immunosorbent assay 
were prepared in the laboratory. 
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1.3. Bacterial Strains 
 Escherichia coli strain BL21 (DE3) was used for expression of His-tagged wild type 
CHIP and for expression of soluble scFv-fragments; TG1 was used for generation of 
phage-displayed antibody libraries used in solid-phase panning and for expression of 
soluble scFv-fragments. 
 
1.4. Equipment and Applications 
 Sonicator: MSE Soniprep 150 Plus ultrasonic disintegrator. 
Centrifuges: 5810R and 5415R (Eppendorf); Sorval RC6 Plus rotor Fiberlite F21-
8x50y (ThermoScientific). 
Photometers and Microplate readers: Spectrophotometer Lambda Bio (Perkin 
Elmer); Fluoroskan Ascent™ FL Microplate Fluorometer and Luminometer 
(ThermoScientific); Spectrophotometer NanoDrop 2000c (Thermoscientific). 
Gel electrophoresis equipment: Mini-PROTEAN Tetra Vertical Electrophoresis 
Cell (Biorad); Mini Trans-Blot cell (Biorad); PowerPack Basic Power Supply (Biorad). 
Film Processor: SRX-101A Film processor (Konica Minolta). 
Software: Windows 7 and Windows 10 OS (Microsoft); Microsoft Office and Excel 
2013 (Microsoft); Chromas Lite. 
 
2. Methods 
 2.1. Transformation of E. coli by heat shock 
Aliquots (50 µl) of competent cells were thawed, gently mixed with plasmid DNA 
and incubated on ice for 30 minutes. Then the cells were exposed to a temperature of 
42ºC for 1 minute followed by a 2 minutes’ incubation on ice. Afterwards 1 mL of LB 
medium was added to the culture and incubated at 37ºC for 1 hour. A 150 µL fraction of 
the culture was plated onto a LB-Agar plate supplemented with the suitable antibiotics and 
incubated at 37ºC overnight. 
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2.2. His-tagged CHIP Production and Purification 
Competent bacterial cells BL21(DE3) were transformed with pET15b-CHIP (His-
CHIP, WT) construct as described above in “Transformation of E. coli by heat-shock”. A 
colony was picked and incubated in LB supplemented with ampicillin overnight at 37ºC 
and 250 rpm. This culture was then used to seed 2 L of LB and incubated at 37ºC until 
OD600 reached ~0.8. Protein expression was induced with 0.5mM IPTG at 30ºC until 
OD600 reached 1.3. The cultures were then centrifuged at 6000 g for 20 minutes at 4ºC. 
The pellet was resuspended, sonicated and then centrifuged at 13000 rpm for 15 minutes 
at 4ºC. The supernatant was filtered and the protein was purified using its His tag through 
immobilised metal ion affinity chromatography with Ni2+-NTA agarose beads (Qiagen) in a 
disposable column (Mobitec). Elution was performed with buffer containing 20 mM Tris 
(pH = 8), 150 mM NaCl and 300 mM Imidazole. To finalize, a desalting step was performed 
using Zeba Spin Desalting Columns (Pierce) and the final storage buffer was 20 mM Tris 
(pH = 8), 15 mM NaCl. Protein was quantified by A280 absorption on a NanoDrop 
Spectrophotometer and its purity evaluated with Coomassie stained SDS–PAGE gels. 
 2.3. SDS-PAGE 
Polyacrylamide SDS gels of appropriate percentage (12% or 15%) were used for 
separation of protein samples. The samples were mixed with 2x SDS sample buffer (25% 
Glycerol, 5% SDS, 0.3 M Tris pH 6.8, bromophenol blue, 20% DTT, MilliQ water) in a ratio 
of 1:1, heated for 3 to 5 minutes at 95ºC and then allowed to return to room temperature 
before being loaded onto the gel along with prestained protein markers. The gels were run 
in Tris-Glycine-SDS running buffer at a constant voltage of 170 V until the dye front 
reached the end of the gel. 
 
2.4. Coomassie Staining 
Gels were submerged in Coomassie Blue stain (45% Methanol, 20% Glacial Acetic 
Acid; Brilliant Blue R-250 (ThermoFisher) for 1 hour. After discarding the Coomassie stain 
the gel was washed in destaining solution for 5 minutes, the destain was removed, fresh 
was added and left shaking until the protein bands could be easily distinguished in the gel. 
In order to accelerate destaining the destain solution was changed several times. 
 2.5. Biopanning 
Microtiter wells (Costar) were coated overnight at 4 °C with 1 µg of His-CHIP and 
CHIP-K30A in 0.1 M bicarbonate buffer, pH 8.6. The wells were washed with sterile PBST 
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and to decrease nonspecific binding, 3% BSA in PBST was added for 1h at room 
temperature. Meanwhile a canine naïve phage library build from dog spleens was diluted 
in BSA and added to a blank well, as pre-clearing step. After 1h of incubation the phage 
library was transferred to the CHIP coated wells and incubated for 1h. The plate was 
extensively washed with sterile PBS-T and the bound phages were eluted in 100 µl 
triethylamine (100 nM), and neutralized with 22 µL of 1 M Tris/HCl, pH 7.4. Eluted phage 
were amplified by infection of fresh E. coli TG1 cells in the presence of helper phage 
M13KO7 (New England BioLabs) and kanamycin (50µg/mL). The phages were purified 
from the culture supernatant by PEG/NaCl (20% polyethylene glycol 6000, 2.5 M NaCl) 
precipitation and resuspended in PBS. The phage obtained were then further selected with 
two more rounds of biopanning and the binding ability of all three rounds was tested as 
described in ‘Polyclonal Phage-ELISA’. 
 2.6. Polyclonal phage-ELISA 
Biopanning was monitored using polyclonal phage-ELISA. Wells were coated 
overnight with 1 µg His-CHIP and CHIP-K30A, washed five times with PBS-T and blocked 
with 3% BSA for 1h. Phages obtained from each round of panning were added to the 
corresponding wells. After one hour incubation at room temperature, the wells were 
washed and anti-M13 antibody conjugated to HRP was added to each well and incubated 
for one hour. The microtiter plate was then washed and electrochemical luminescence 
was quantified using a luminometer. 
 2.7. Monoclonal scFv Isolation 
Biopanning rounds 2 and 3 were used for selection of monoclonal scFv antibodies. 
E. coli TG1 bacteria transformed with phagemids were plated on LB agar containing 100 
µg/ml of ampicillin and grown overnight at 37ºC. Single colonies were picked and cultured 
in LB medium containing 100 µg/ml of ampicillin and 0.1% of Glucose and grown at 37ºC, 
constituting a starter culture. After 4h, 8 µL of the starter culture was used to inoculate 
800 µL of LB supplemented with Ampicillin and Glucose and grown for 2h at 37ºC. A 
glycerol stock was made from the remaining starter culture. Protein production was 
induced with 1 mM of IPTG overnight at 30ºC. The cells were lysed through multiple 
freeze/thaw cycles and the plate was centrifuged for 10 minutes at 4000 g. 
 2.8. Soluble ScFv Binding Assay 
Ninety six well microtiter plates were coated with the target proteins (His-CHIP and 
CHIP-K30A) in bicarbonate buffer pH 9.6 and left to incubate overnight at 4ºC. The plates 
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were washed five times in PBST and blocked with 3% BSA for 1h. Lysate containing scFv 
was added to the wells and incubated for 1h. The wells were washed and protein A 
conjugated to HRP was added. After 1h of incubation the microplate was washed and 
electrochemical luminescence was quantified using a luminometer (Labsystems 
Fluoroskan Ascent FL). The clones with the highest affinity were then further validated 
by probing against the target they were designed against, the other target and α-
synuclein (as a negative control).  
 2.9. Isolation of plasmid-DNA from E. coli 
Plasmid DNA from the clones with highest affinities were isolated from TG1 cells 
grown from the starter culture using QIAprep Spin Miniprep kit (QIAGEN), according to 
the manufacturer’s protocols. Yield and quality of plasmid DNA was analysed using a 
NanoDrop spectrophotometer. The isolated plasmid DNA was stored at -20ºC. 
 2.10. ScFv clones Sequencing 
 A sample of each clone’s plasmid DNA was sent for Sanger sequencing at Source 
BioSciences (BioCity Scotland, Lanarkshire) with the primer GIIIFOR (sequence: 
ACTTAAAAGACATACTCCAAAACG). Once received, DNA sequences were translated to 
protein sequences using the software ExPASy - Translate tool (Gasteiger et al., 2003) and 
aligned with Clustal Omega (Sievers et al., 2011).  
 2.11. Medium Scale scFv Production and Purification in TG1 cells 
 Selected scFv clones were picked from the starter culture and grown overnight in 
5 ml of LB supplemented with 100 µg/ml of ampicillin and 0.1% Glucose at 37°C and 250 
rpm. This culture was then used to seed 250 mL of LB (plus 100 µg/ml of ampicillin and 
0.1% Glucose), which was cultured for approximately 4 h. Protein production was then 
induced with 1 mM IPTG overnight at 37°C and 250 rpm. Bacteria were harvested by 
centrifugation (4000 rpm, 4°C, 10 min), resuspended in 10 ml of PBS 1% Triton-X and 
incubated for 30 minutes at 4ºC in a rotating wheel. Lysis was achieved by sonication. Cell 
debris was removed by centrifugation (13000 rpm, 4°C, 10 min), and the supernatant was 
collected. Antibody fragments were purified using 500 µL of Protein A resin (Amintra). 
Soluble scFv concentration and purity was estimated by InstantBlue (Expedeon) stained 
SDS–PAGE gels. 
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2.12. Medium Scale scFv Production and Purification in BL21-DE3 cells 
 Competent bacterial cells BL21 (DE3) were transformed with scFv plasmids 
extracted as was described in ‘Isolation of plasmid-DNA from E. coli’ using the heat shock 
method as described in ‘Transformation of E. coli by heat shock’. Single colonies were 
picked from the plate, inoculated into 100µL of LB medium supplemented with 100 µg/ml 
of ampicillin and incubated at 37ºC, in order to grow a starter culture. After 4h, 8 µL of the 
starter culture was used to inoculate 800 µL of LB medium with Ampicillin and grown for 
2h at 37ºC. A glycerol stock was made from the remaining starter culture. Protein 
production was induced with 1 mM of IPTG overnight at 30ºC. The bacterial cells were 
lysed through multiple freeze/thaw cycles and centrifuged for 10 minutes at 4000 g. The 
lysate was used in a binding assay in order to determine if the bacterial cells’ 
transformation had been successful. Afterwards the clones were picked from the starter 
culture and grown overnight at 37°C and 250 rpm in 5 mL of LB medium complemented 
with 100 µg/ml of ampicillin. This culture was then used to seed 250mL of fresh LB-
Ampicillin, and grown until OD600~0.6. ScFv antibodies production was then induced with 
1 mM IPTG overnight at 37°C and 250 rpm. Bacteria were harvested by centrifugation 
(4000 rpm, 4°C, 10 min), resuspended in 10 ml of PBS 1% Triton-X and incubated for 30 
minutes at 4ºC in a rotating wheel followed by sonication. Cell debris were removed by 
centrifugation (13000 rpm, 4°C, 10 min), and the supernatant was collected. Antibody 
fragments were purified using 40 mg of Protein A Sepharose CL-4B (GE Healthcare). 
Soluble scFv concentration and purity was estimated by Coomassie Brilliant Blue R-250 
stained SDS–PAGE gels. 
 2.13. Binding Assays  
 Purified Protein (α-synuclein, His-CHIP, CHIP-K30A) was immobilized in microtitre 
plates in 0.1M NaHCO3 (pH 8.6) overnight at 4ºC. Following washes in PBS supplemented 
with 0.1%Tween, the wells were blocked with 3% BSA in PBS. A titration of the protein of 
interest was added for 1h at room temperature. Binding was detected using anti-α-
synuclein or anti-CHIP 3.1 followed by HRP-tagged anti-mouse secondary or using 
ProteinA HRP-conjugate. Electrochemical luminescence was quantified using a 
luminometer.  
 2.14. Native Gel 
  Polyacrylamide gels of appropriate percentage (8%) were used for separation of 
protein samples. The samples were mixed with 2x Native sample buffer (25% Glycerol, 
0.3M Tris pH 6.8, bromophenol blue, MilliQ water) in a ratio of 1:1, heated for 3 to 5 minutes 
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at 95ºC and then allowed to return to room temperature before being loaded onto the gel. 
The gels were run in Tris-Glycine running buffer at a constant voltage of 85V until the dye 
front reached the end of the gel. 
 
2.15. Ubiquitination Assays 
 For in vitro ubiquitination assays, 0.1 µg purified α-synuclein was incubated with 3 
µg of His-CHIP, 1 µM UbcH5α, 100 nM Ube1, 2 µg ubiquitin, and 3 mM ATP (Sigma), in 
reaction buffer (25 mM HEPES, 10 mM MgCl2, H2O, 0.5 mM DTT, 1 mM Benzamidine and, 
when mentioned 0.05% of Triton-X or n-Dodecyl-β-D-maltoside (ULTROL grade; 
Calbiochem)) for up to 60 minutes at 30ºC. If required, scFvs were added to the 
ubiquitination mix before the start of the reaction with CHIP (see legends for details). 
Samples were analysed by SDS-PAGE using 12% or 15% polyacrylamide gels followed 
by Western blot with anti-α-syn mouse monoclonal or anti-CHIP 3.1 mouse monoclonal 
and anti-mouse secondary. 
 2.16. Immunoblotting 
 Separated proteins were transferred from the SDS-PAGE gel to nitrocellulose 
membrane (0.2µm, Advantec). The transfer was carried out in Glycine/Tris/Methanol 
transfer buffer at a constant amperage of 400mV for 1h15. Membranes that were to be 
revealed with anti- α-synuclein antibody were incubated in 0.4% Paraformaldehyde (PFA) 
for 30 minutes and rinsed with MilliQ water (Millipore) water before blocking. Blocking is 
performed overnight with 5% (w/v) skimmed milk powder in PBS. After blocking, incubation 
with primary antibody diluted in blocking buffer was carried out for 1h at room temperature, 
followed by four 5 minutes washes with shaking in PBST. Anti-CHIP 3.1 (1:2000), anti- α-
synuclein (1:2000) and anti p53 DO-I (1:1000) were used as primary antibodies and 
detected with secondary polyclonal anti-mouse antibody coupled to HRP (1:1000) diluted 
in blocking buffer incubated with the membrane for 40 minutes. After another set of four 
washes in PBST of 5 minutes with shaking, the blot was overlaid with a mix of ECL 
reagents I and II (1:1) for one minute, dried and exposed to x-ray film for the preferred 
period of time. The film was developed with a film processor. 
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IV. RESULTS 
 
  Expression and Purification of His-CHIP 
 In order to obtain CHIP for biopanning, scFv characterization and the enzyme 
assays, a plasmid encoding wild type Histidine tagged CHIP protein was expressed in E. 
coli BL21 (DE3) according to the already optimized protocol described above. 
Previously to protein purification, bacterial culture samples collected before and 
after induction with IPTG were pelleted, resuspended in PBS, sonicated and the cell debris 
pelleted in order to collect whole protein extract. A fraction of whole protein extract was 
further centrifuged to obtain soluble protein extract. The extracts were then separated 
using an SDS-PAGE gel and stained with Coomassie Brilliant Blue to test the expression 
and confirm that CHIP had been produced successfully, before initiating the purification 
process. 
 
  
  
 
 
 
 
 
 
 
The expression trail confirms that a protein of approximately 35kDa, which is 
consistent with the expected molecular weight for CHIP, was successfully overproduced 
in an appreciable concentration, after induction with IPTG (Figure 9). CHIP was expected 
to be fully present on the soluble fraction, after induction with IPTG, but there is less of the 
35 kD band in this fraction than in the whole protein fraction; this may be due to excessive 
centrifugation of the sample or the presence of other proteins with the same molecular 
weight as CHIP that are not present in the soluble fraction.  
Figure 9. SDS-PAGE analysis of expression trail for CHIP protein. 
Bacterial culture samples were prepared and resolved on 12% (w/v) SDS-PAGE gel and then stained with Coomassie brilliant blue.  M: Molecular weight marker; 1: 10µL of Whole Protein Before IPTG fraction; 2: 10µL of Whole Protein After IPTG fraction; 3: 10µL Soluble Protein Before IPTG fraction; 4: 10 µL of Soluble Protein After IPTG fraction. 
1        2         3         4 M 
170 – 
 100 –   70 – 
   55 – 
   40 –    35 –     25 –        15 –   
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Following protein purification, concentration was evaluated on a Nanodrop 
spectrophotometer and an SDS-PAGE gel was run to assess the efficiency of the 
purification process and confirm the concentration of the purified protein, by comparison 
with BSA standards.  
 M1 M2 Average 
Concentration (mg/mL) 3.217 3.231 3.224 
A260/A280 0.64 0.64  
Table 2. Determination of the Concentration of CHIP after purification by NanoDrop. 
 
Two separate measurements were carried out, using the protein buffer to establish 
a baseline, and the values obtained were very similar and point towards a concentration 
around 3.2mg/mL. The 260/280 absorbance ratio is very close to the optimal value (0.6) 
which indicates there is no contamination with nucleic acids (table 2). 
 
 
 
 
 
 
 
 
 
The SDS-PAGE gels shows that the purification was successful although some 
protein seems to have remained in the flow through and some was lost in the final wash 
(Figure 10). The comparison with the BSA standards is in agreement with the Nanodrop 
quantification since the purification yield seems to be higher than 2mg/mL. As such it will 
be considered that purified His-CHIP is at a concentration of 3.2mg/mL, as indicated by 
the Nanodrop. 
 
M Lys FT W FW 1 3 2 4 5 
170 – 
  100 –   70 – 
   55 –    40 –    35 –     25 –        15 –   
Figure 10. SDS-PAGE analysis of CHIP's affinity purification. 
Affinity purified His-CHIP obtained from the expression system was resolved on 12% SDS-PAGE gel and posteriorly stained with Coomassie brilliant blue. M: Molecular Weight Marker; Lys: 10µL of Lysate; FT: 10µL of Flow Through, W: 10µL of washing fraction; FW: 10µL of Final washing fraction; 1: 1µL of His-CHIP; 2: 0.66µL of His-CHIP; 3: 0.33µL of His-CHIP; 4: 1 µL of 2mg/mL BSA standard; 5: 1µL of 1mg/mL BSA standard. 
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 ScFv development and selection 
 The phage library was subjected to three rounds of biopanning against 1ug of His-
tagged CHIP and untagged CHIP K30A immobilized on the surface of a microtiter plate 
well. For each round of panning, the phages were pre-cleared on a blocked well to exclude 
phages binding to the blocking agent. After the biopanning rounds the goal is to have two 
phage libraries of single chain antibodies that bind to CHIP and to CHIP-K30A.  
At the end of rounds 1 and 2, small fractions of each library were used in the 
following round and the remainder was stored for future analysis. After the biopanning, the 
three polyclonal rounds of each library were probed for binding against the target they had 
been selected against, the second target and uncoated wells. The results are presented 
in the graph below.  
 
 
The biopanning was successful as there was an increase in binding to the target 
following the first two rounds of panning (Figure 11). Since no substantial increase was 
obtained on the third round of panning, no more rounds were performed. The results also 
show that the polyclonal pools of phages show no specific affinity for CHIP or CHIP-K30A, 
binding indiscriminately to both targets despite having only been selected against one. 
This was to be expected as the difference between the two targets resides in the change 
of only one amino acid. Although this change produces structural alterations that may 
impact binding, at this stage, the phage libraries were polyclonal and as such there were 
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Figure 11. Enrichment of CHIP and CHIP-K30A binding phages through biopanning. 
CHIP (A) or CHIP-K30A (B) phages obtained following each round of biopanning were tested against CHIP, CHIP-K30A and uncoated wells by Polyclonal Phage ELISA. Phages were detected with anti-M13 Phage polyclonal antibody conjugated with Horseradish peroxidase (HRP) and enhanced chemiluminescence. Binding is expressed in relative light units (RLU)and have been plotted as mean ± SD of duplicates. 
A B 
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scFv antibodies with different binding affinities and probably capable of binding to different 
zones of the target proteins. 
After the biopanning, dilutions of the second and third round of the CHIP and the 
CHIP-K30A phage libraries were used to infect E. coli TG1 and these were then plated out 
in agar-LB plates and grown overnight. Afterwards, 48 colonies from each library were 
randomly selected from both dilutions and grown in microtiter plates. Expression of soluble 
scFv-antibodies was induced by 1mM IPTG and rupturing of the bacterial cells was 
achieved through several freeze-thaw cycles. The supernatant obtained, after pelleting the 
cell debris, was used to test the scFv specificity in direct ELISA experiments against 
bacterially expressed CHIP or CHIP-K30A according to the target that had been used for 
the panning process and against α-synuclein as a negative control. 
 
 
Overall the signal for binding to His-CHIP (Figure 12) was quite low and most of 
the clones selected did not present visible binding affinity for the target protein as the signal 
for CHIP coated wells was similar to the signal for wells coated with α-synuclein, the 
negative control. Inclusively there was one clone that appear to have a higher affinity for  
α-synuclein than CHIP.  
As for the CHIP-K30A library (Figure 13), several clones seemed to bind to the 
target and there was one clone (11F) that presented a particularly high binding capacity in 
Figure 12. Screening of CHIP library selected clones in soluble scFv binding assay. 
Binding activity of 48 randomly selected scFv-fragments after biopanning, against 0.1µg CHIP and 0.1µg alpha synuclein was revealed by direct ELISA. Bacterial supernatant was added and bound scFvs were detected with 1:1000 diluted ProteinA polyclonal antibody conjugated to horseradish peroxidase and enhanced chemiluminescence. The results are given in relative light units. 
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comparison with the others, indicating that it might be a promising scFv antibody to take 
forward.  
 
 
 
In this stage it is already possible to perceive the diversity of binding affinities 
present in the polyclonal pool of phages although it is likely that some of the differences 
observed may be due to different expression rates of different clones. 
As these assays were performed without duplicates, the clones with the highest 
binding for each library were selected for further validation, in order to confirm the binding 
to the target used in the biopanning rounds and check for cross-reaction with the other 
target.  
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Figure 13. Screening of CHIP-K30A library selected clones in soluble binding assay. 
(A) Binding activity of 48 randomly selected scFv-fragments after biopanning against 0.1µg CHIP-K30A and 0.1µg α-synuclein was revealed by direct ELISA. (B) Same as in (A) but with a smaller scale on the y axis to highlight other binders that, despite not being as strong binders as 11F, presented a considerable signal, clearly demarked from the negative control. The results are given in relative light units. 
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 Sequencing analysis and validation of scFv 
 In order to further validate the scFv clones with the highest binding affinity, for the 
target from each library, the clones were probed against CHIP and CHIP-K30A, 
independently of which target was used to design them, and also against α-synuclein as 
a negative control, by direct ELISA. This would confirm that the generated scFv were 
capable of binding to the target and determine if any of them were specific for the wild type 
or the mutant CHIP.  
  
All the selected scFv antibodies exhibit a higher binding affinity for the mutant 
CHIP-K30A than for wild type his-tagged CHIP, independently of the target they were 
selected for (Figure 14). This can be explained by the more stable conformation that the 
mutant adopts. The mutation decreases the degree of flexibility of the protein possibly 
decreasing the number of conformations it can adopt and resulting in a higher binding 
affinity. 
As it is likely that some of these clones are actually the same, 12 of the 14 clones 
presented above were sent for sequencing so that it was possible to analyse their 
sequences and take forward only different clones. The clones 6A and 6B were excluded 
for presenting lower binding affinities. 
In the 12 clones sent for sequencing, there were 8 different scFv antibodies. DNA 
sequences were translated to protein sequences using ExPASy - Translate tool and 
aligned with Clustal Omega software in order to be compared (Figure 15). 
Figure 14. Validation of the scFv clones with highest affinity. 
Binding activity of the 14 selected scFv-fragments with the highest binding from both His-CHIP (A) and CHIP-K30A (B) libraries against 0.1ug/mL WT CHIP, 0.1ug/mL CHIP-K30A and 0.1ug/mL alpha synuclein was revealed in soluble scFv binding assay. The results are given in relative light units and have been plotted as mean ± SD of duplicates. 
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As expected, generally, the framework regions show a high degree of similarity 
across all the sequences with most of the different amino acids having been exchanged 
by groups with similar properties. The CDRs in the light chain present the largest variety 
of sequences among the 8 clones, while in the heavy chain, CDR1 and CDR3 present only 
three different sequences each, among all the clones, and CDR2 has 6 different 
sequences. 
 
Finally, the reactivity of the 8 selected clones was also analysed against untagged 
bacterially produced CHIP. This aimed to demonstrate the scFvs selected with His-CHIP 
(4C and 5D) were specific for epitopes in CHIP and not the histidine tag and that the scFvs 
were capable of binding to a form of CHIP without tags or mutations, that can alter the 
dynamics of the protein. 
  
 
 
All the clones displayed binding affinity for the untagged CHIP; in the case of 4C 
and 5D it also confirms that the scFv antibodies are specific for the CHIP protein and not 
for the histidine tag (Figure 16). 
In summary, phage display technology allowed the selection and isolation of 8 
single chain variable fragments specific for CHIP that bind to it with different degrees of 
reactivity which can be altered by small modifications in the protein as was shown by the 
different binding affinities observed for His-tagged CHIP and mutant K30A. 
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Figure 16. Reactivity of selected scFv clones against untagged CHIP. 
A microtiter plate was coated with 0.1µg/mL of untagged CHIP and 0.1 µg/mL of α-synuclein and incubated overnight. The coating was washed off and the wells were blocked and periplasmic supernatant was added. Bound scFvs were detected with 1:1000 diluted ProteinA polyclonal antibody conjugated to horseradish peroxidase and enhanced chemiluminescence 
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 Soluble Expression and Purification of scFv clones  
 In order to overcome differences based on expression in microtiter plates and 
obtain purified scFvs that could then be used in other assays, the selected clones for each 
target were subjected to medium scale expression.  
Initially the scFv clone that had shown the highest signal, 11F, was grown from the 
E.coli TG1 starter cultures generated at the time of the selection of monoclonals, in LB 
medium enriched with Ampicillin and 1% of Glucose. The addition of glucose, inhibitor of 
the lacZ promoter, was meant to repress the pIII fusion expression which is regulated by 
the lacZ promoter in the phage vector. Protein expression was induced by 1mM of IPTG 
overnight at 30ºC. Purification was accomplished using ProteinA beads and scFv were 
eluted from the beads with 0.2M Glycine pH 2. Five fractions were collected and 
immediately neutralised with 1M Tris pH 9. 
The efficiency of the purification process was evaluated and the concentration of 
the fractions determined with SDS-PAGE gesl where samples of the lysate, flow through, 
washes, elution fractions and BSA standarts were run. The gels were stainned with 
InstantBlue since standard Comassie blue was not sensitive enough to detect the bands 
of eluted scFv (data not shown). 
 
 
Figure 17. Soluble Expression, purification and quantification of scFv 11F in E. coli TG1. 
Proteins were separated on 12% SDS-PAGE gel and stained with InstantBlue (A) SDS page analysis of scFv 11F Purification.. M: Marker; Lys: 10 μL of lysate; FT: 10 μL of flow through; W: 10 μL of washing fraction; FW: 10 μL of final washing fraction; F1, F2, F3, F4, F5: 10 μL of elution fractions. (B) Quantification of scFv 11F. F1, F2: 10 μL of elution fractions; BSA standards: 1µL of each BSA standard was loaded into the gel. 
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The production and purification process was successful but the yielded low 
concentrations of scFv (Figure 17A). The first elution fraction showed the presence of a 
15kDa protein which is presumably a low affinity contaminant that elutes first from the 
column. It is possible to see bands of approximately 30kDa, in the elution fractions, which 
is, generally, the approximate molecular weight for scFv antibodies. The second elution 
fraction presents the highest concentrations of scFv; fraction 3 seems to have a very light 
band too but fractions 4 and 5 don’t have any scFv. The concentration of fraction 2 was 
estimated, by SDS-PAGE with BSA standards, as approximately 0.02mg/mL. This fraction 
was further used in other assays. 
As the production and purification did not yield a great amount of scFv, it was 
necessary to do so again. The second time, E.coli BL21-DE3 cells were used; these, unlike 
TG1, can read the amber stop codon upstream of the gene pIII sequence, resulting in 
expression of non-fused scFv. The bacterial cells were transformed with scFv plasmids 
using the heat shock method and starter cultures were grown.  
Before proceeding with the production and purification of the scFv, the success of 
the BL21-DE3 cells transformation was assessed. For this, small bacterial cultures were 
grown and scFv production was induced with IPTG. The cells were lysed through multiple 
cycles of freeze/thaw and the lysate was used in a binding assay to determine if the cells 
were producing scFv.  
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Figure 18. Transformation of E.coli BL21-DE3 with scFv plasmids. 
Transformation of BL21-DE3 bacterial cells with scFv plasmids was assessed by inducing scFv production and detecting binding activity against 0.1ug/mL CHIP in a direct ELISA. Bacterial lysate was added and bound scFvs were detected with 1:1000 diluted ProteinA polyclonal antibody conjugated to horseradish peroxidase and enhanced chemiluminescence. Results are shown in RLU and were plotted as mean ± SD of triplicates. 
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The binding assay showed there was production of functional scFv antibodies 
capable of binding to His-CHIP (Figure 19); thus the transformation was successful and 
so the production and purification process was carried out. 
A small culture was grown overnight from the starter culture and then diluted in 
250mL of LB enriched with ampicillin. The OD was carefully monitored and scFv 
production was induced with 1mM IPTG once OD~0.6. The cultures were then incubated 
overnight at 30ºC. 
Of the eight selected single chain fragments all were produced (data not shown) 
but only four were successfully purified from protein A beads. Five fractions of each scFv 
fragment were eluted with 0.2M Glycine and immediately neutralized with 1M Tris. 
Following the purification, the SDS-PAGE gel revealed the presence of a single band of 
approximately 30 kDa for scFvs 7A, 7G and 11F and the presence of a band of 
approximately 35 kDa for scFv 4C (Figure 19). 
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Figure 19. SDS-PAGE analysis of affinity purified scFvs 4C, 7A, 7G, 11F. 
Selected scFvs (4C, 7A, 7G and 11F) were expressed in the E.coli strain BL21-DE3 upon induction with IPTG. Expressed scFvs were purified with Protein A beads. Proteins were separated on 12% SDS-PAGE gel and stained with Coomassie Blue stain. After an hour the gels were distained. M: Marker; Lys: 10 μL of lysate; FT: 10 μL of flow through; W: 10 μL of washing fraction; FW: 10 μL of final washing fraction; F1, F2, F3, F4, F5: 10 μL of elution fractions. 
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Afterwards, the scFv concentration was estimated through a Coomassie gel with 
BSA standards. The first fractions of 4C, 7A and 11F and the second fraction of 7G seem 
to have a concentration of approximately 0.1mg/mL and were chosen to be further used 
in subsequent assays. It is also possible to verify that 4C does indeed migrate slower than 
the remaining scFvs (Figure 20). 
  
 
 
 
 
 
 
 
 
 
 
 
 Characterization of Purified scFv clones 
 In order to better characterize the purified scFv antibodies and to try to understand 
their behaviour several assays and analysis were conducted.  
Initially, based on the scFv amino acid sequences, a set of biophysical and 
biochemical parameters were computed with the Expasy server’s Protparam Tool and can 
be reviewed in the table 3. 
The length of these four clones varies between 240 and 249 residues and the 
predicted molecular weight is around 26kDa. Considering figure 14 and comparing with 
this information, it is noticeable that all the scFvs run at a molecular weight slightly higher 
than anticipated. 7G presents the highest predicted molecular weight and in agreement 
with that runs slightly higher than 11F and 7A. However, 4C is the clone that migrates 
slower, even though it presents one of the lowest molecular weights. Analysing table 3 
none of the parameters seems to suggest a reason as to why this would happen so it might 
be a structural problematic such as rigidity of a certain area or insufficient denaturation by 
SDS. 
11F                    7G                 4C            7A           BSA (mg/mL) 
M    F1     F2    F3      F1      F2      F3      F1    F2       F1    F2    0.1    0.2     0.5     1 
170 – 
 100 –   70 – 
   55 –   
   40 –    35 –    25 –  
   15 – 
   10 – 
Figure 20. Quantification of purified scFv fractions. 
Proteins were separated on 12% SDS-PAGE gel and stained with Coomassie Blue. M: Marker; F1, F2, F3: 10 μL of elution fractions; BSA standards: 1µL of each BSA standard was loaded into the gel. 
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Primary Structure Comparison 
Clones No. of residues Molecular Weight pI Hidropathicity1 Aliphatic Index2 Instability Index3 Extinction Coeficient4 
4C 240 25.65 5.56 -0.238 71 41 43110a / 42860b 7A 242 25.83 5.17 -0.253 68 32 44600a / 44350b 
7G 249 26.19 6.72 -0.232 69 40 40130ª / 39880b 11F 243 25.60 5.91 -0.262 68 40 45630ª / 45380b 
 
Table 3. Comparison of the Primary Structure of the purified scFv Antibodies. 
These values were estimated using the ProtParam tool (http://www.expasy.org), based on the amino acidic structure of the scFv sequence. 1Grand average of hydrophathicity (GRAVY) is calculated as the sum of hydropathy values of all the amino acids, divided by the number of residues in the sequence (Kyte and Doolittle, 1982) and ranges from -1.5 to 1.5. A more negative value implies a lower hydrophobicity overall. 2Statistical index defined as the relative volume of a protein occupied by aliphatic side chains that can be considered a positive factor for the increase of thermostability of globular proteins (Ikai, 1980). 3Statistical index based on the observation that there are certain dipeptides, the occurrence of which is significantly different in unstable proteins compared with those in stable ones (Guruprasad et al., 1990). A protein with an index under 40 is predicted stable whereas a value over 40 anticipates that the protein may be unstable. 4It has been shown that it is possible to estimate the molar extinction coefficient of a protein from its amino acid sequence (Gill and von Hippel, 1989). Two values are produced, the first one (a) showing the computed values assuming that all cysteine residues appear as half cystines, and the second (b) assuming that all cysteine residues are reduced. 
 
The clones 4C, 7G and 11F present borderline in vitro instability indexes but for 7A 
the value is lower than 40 suggesting that this scFv is more stable than the others. 
Additionally, the pI values (under 7) suggest that intracellularly the scFvs would adopt a 
negative charge and the negative GRAVY indicates hydrophilicity. 
 
A direct ELISA was performed to examine the reactivity of the purified scFvs 
against His-CHIP and CHIP-K30A. To this end, the proteins were immobilized in microtiter 
plates and incubated with a titration of scFv. 
In agreement with what had been described before, generally, all the clones are 
able to bind more strongly to the mutant than to wild type CHIP while presenting negligible 
binding for α-synuclein (Figure 21). Given the scFv ability to bind specifically to CHIP in 
ELISA, it is possible to conclude that all clones expressed functional scFvs. 
All the clones display a rise in binding as the amount of scFv increases although 
there are different degrees of reactivity for the different clones. For the mutant CHIP-K30A, 
4C is the weakest binder and 11F the strongest, as had already been suggested, whereas 
7A and 7G present relatively similar reactivity. Regarding the wild type CHIP, 4C and 7A 
show the weakest binding and 7G and 11F the strongest.  
 It is also noteworthy that while the other clones show a great disparity between 
the reactivity against the mutant and wild type CHIP, 7G presents a only a small difference. 
While scFv 7A shows the greatest difference. This may suggest the scFvs bind to different 
epitopes more or less susceptible to changes in the conformation of CHIP. 
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Considering the differences shown above together with the sequences of the scFv. 
ScFv 4C and 7A share most of the same heavy chain fragment, differing only in two amino 
acids in the CDR2 however they present a very different reactivity for CHIP. This suggests 
that either the bulk of the influence in binding resides on the light chain fragment or that 
the switch of two amino acids (threonine and Histidine) with bulkier side chains by two 
serines is enough to increase the binding to CHIP. 
 
 
 
Figure 21. Binding of scFv purified from E.coli  
50ng of His-CHIP, mutant CHIP-K30A and α-synuclein were coated on microtiter plate wells and a titration of the affinity purified scFv was added. Bound scFvs were detected by using Protein A HRP conjugate (1:1000). Results are displayed in RLU as mean ± SD of triplicates.The assay was run in the same plate and using the same reagents for all the scFvs in order to allow for a meaningful comparison between the binding affinities. 
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 Light chain Clones CDR1 CDR2 CDR3 4C SGE--NLNKYYVR KDTERPS ESPVSTDTAAV 7A SGRTNDIGIVGAS SNGNRPS QPFYTTFDSHV 7G TGSSSNIGRGYVH GISNRPS SSWDSSLSAAV 11F TGGNSNIGGNGVG GDHYRPS SSWDGSLGRHV  :* .  :     .      *** .    :    * 
Table 4. Comparative summary of CDRs’ sequence from the purified scFv. 
‘*’ (asterisk) indicates positions which have a single, fully conserved residue; ‘:’ (colon) indicates conservation between groups of strongly similar properties, scoring >0.5 in the Gonnet PAM 250 matrix; ‘.’ (period) indicates conservation between groups of weakly similar properties, scoring ≤ 0.5 in the Gonnet PAM 250 matrix. Matching amino acids are indicated in green.  
 
 An assay was also performed to evaluate the behaviour of the scFv in the presence 
of a CHIP titration. A titration of His-tagged CHIP was immobilized on a microtiter plate 
and incubated with scFv. 
 
 
The four clones present very different binding patterns in the presence of a titration 
of CHIP but there are in agreement with what had been preciously observed with 11F 
 Heavy Chain Clones CDR1 CDR2 CDR3 4C SYYMY RITHDGSITYYADAVKG TAI-------GSD 7A SYYMY RISSDGSTTYYADAVKG TAI-------GSD 7G SYTMS AINSGGSSTKYTDAVKG PAPRTAAPLNFDY 11F SYYMY RISSDGTDTFYADAVKG SRVV------GAD  ** * *.   *: * *:*****  
Figure 22. Reactivity of purified scFvs with CHIP Titration 
(A) Binding Assay was performed by coating microtiter plates with a titration of His-CHIP (0-100ng) and 10ng of purified scFvs were added. Bound scFvs were detected by using Protein A HRP conjugate (1:1000). The assay was run in the same plate and using the same reagents for all the scFvs in order to allow for a meaningful comparison between the binding affinities. (B) Same as (A) but combined in the same graph. Results are displayed in RLU as mean ± SD of triplicates. 
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being the scFv with capacity to form more stable complexes, followed by 7G and 7A. While 
4C appears to recognize the titration as small increments in signal can be observed, it still 
has low affinity for His-CHIP. 7A and 11F don’t seem to distinguish very well between small 
concentrations of the protein but 7G presents continuously growing signal and appears to 
start to stabilize towards 100ng of CHIP.  
 
Finally, in an attempt to gain some insight into how the scFv might influence CHIP’s 
structure, the different scFv clones were incubated with His-CHIP and resolved in a Native-
PAGE gel along with a sample of His-CHIP by itself and a control in the scFv buffer 
(Glycine and Tris). 
 
 
 
 
 
 
 
 
 
 
 
The results show a demarked increase in CHIP species that migrate faster on the 
native gel when scFv 11F and 7G are present while this doesn’t happen with 7A and 4C. 
These results are independent of the scFv buffer as the pattern for this control is similar to 
the run of CHIP alone (Figure 23).This suggests that perhaps 11F and 7G are promoting 
the disassembly of CHIP, possibly by binding to an area essential for the association of 
the monomers. 
 
 
Figure 23. Native gel analysis of CHIP bound to scFv. 
(A) His-tagged CHIP (3µg) was incubated by itself (lane 1), with 1µL of scFv buffer (lane 2) or with 0.1µg of scFvs (lanes 3-6) for 30 minutes at 30ºC. 0.1µg of scFv were also incubated on their own in the same conditions (lanes 7-10). Native sample buffer was added and the samples were run in 8% polyacrylamide gels. Detection was performed by Western Blot using anti-CHIP 3.1. (B) The experiment was repeated to clarify the impact of 7A and 4C on CHIP. 
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 CHIP interacts with α-Synuclein in vitro 
 Concurrently with the development and characterization of the scFvs, CHIP’s in 
vitro activity on α-synuclein was studied in order to gain some insight into the possible 
dynamics of this interaction and to establish an assay that would allow the study of scFvs’ 
influence in the activity of the E3 ligase CHIP.  
 
A binding assay was performed with α-synuclein bound to the plate and CHIP in 
the soluble phase and in the alternative orientation. 
 
  
 
 
 
 
 
 
 
 
 
 
It is clear that CHIP is capable of binding to α-synuclein, in the conditions of the 
assay, but only when it is in the soluble phase (Figure 24). This suggests that either CHIP 
binds to the plate using the same interface used to bind to α-synuclein or that the binding 
to the plate restricts the flexibility of CHIP, forcing the protein to adopt a conformation that 
doesn’t allow for binding to α-synuclein. 
Afterwards, and given that CHIP is primarily an E3 ubiquitin ligase, it was studied 
CHIP’s in vitro ubiquitination activity on α-synuclein. 
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Figure 24. CHIP binds to α-synuclein in vitro. 
0.1ug of purified His-CHIP (orange) or α-synuclein (green) was coated onto microtiter plates wells and a titration of α-synuclein (0-200ng) or His-CHIP (0 -200ng), respectively, was added. Bound CHIP was detected by using anti-CHIP 3.1 (1:1000) and α-synuclein with anti-α-synuclein (1:1000), both followed by anti-mouse (1:1000) and detected with ECL and the results are shown in RLU. The data is  representative of two independent experiments and presented as mean ± SD of triplicates. 
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Several variations of the ubiquitination assay were tried but it was not possible to 
see any pattern that could correspond to ubiquitinated α-synuclein (Figure 25) even with 
long exposures.  
There has been some controversy regarding endogenous α-synuclein detection in 
western blot as very different results have been obtained. However it has been proposed 
that crosslinking α-synuclein to the membrane using chemicals as paraformaldehyde 
(PFA), allows for a strong and clear detection (Newman et al., 2013). Even though this 
study is not being conducted with endogenous α-synuclein, a new assay was performed 
and this technique was attempted by incubating the blot in a low concentration of PFA, 
previous to blocking. 
Interestingly, incubation with PFA, resulted in the appearance of bands of 
ubiquitinated α-synuclein, as can be seen in lanes 4-8 when compared with lanes 2 
(control without E3) and 3 (control without ATP) (Figure 26). 
The data shows that CHIP can efficiently bind and ubiquitinate α-synuclein in vitro 
and without the assistance of other cellular components such as Hsp70. It is noticeable 
the presence of a band just under 25kDa which is consistent with the expected molecular 
weight of monoubiquitinated α-synuclein (22.5 kDa; UB-α-syn). Above this band there are 
two more well defined bands and then a more diffuse pattern of multiple higher molecular 
weight forms which may be polyubiquitinated or multi-monoubiquitinated α-synuclein 
((UB)n-α-syn). 
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Figure 25. In vitro ubiquitination of α-synuclein by CHIP. 
Immunoblot of in vitro ubiquitination reactions assembled using ATP, ubiquitin, Ube1, ubcH5α and α-synuclein and started with His-CHIP. The samples were incubated from 10 to 60 minutes at 30ºC and the reaction was stopped with the addition of sample buffer. 
 
FCUP DEVELOPING SYNTHETIC TOOLS TO IMAGE AND MODULATE THE ACTIVITY OF CHIP 53  
 
  
 
 
 
 
 
 
In consequence of these results, a PFA incubation step was added to the standard 
Western blot protocol between the transferring and blocking steps for all membranes that 
would be incubated with anti-α-synuclein antibody. 
Besides the incubation with PFA, the assay was also optimized regarding the 
presence of detergent in the reaction buffer, since the presence of some detergents 
(Chandra et al., 2003) has been shown to change α-synuclein’s structure which could 
influence the ubiquitination reaction. Different concentrations of CHIP were also tested. 
 
 
 
  
  
 
  
 
Figure 27. Optimization of in vitro CHIP/α-synuclein ubiquitination assay. 
Immunoblot of in vitro ubiquitination reactions optimized for detergent presence and concentration of His-CHIP. The reactions were started with 3µg of His CHIP except when indicated. The samples were incubated for 50 minutes at 30ºC and the reaction was stopped with the addition of sample buffer. Two different detergents were used: Tríton-X (T-x ) and  n-Dodecyl-β-D-maltoside (D). The results are representative of two independent experiments.  
Lane  Alpha-synuclein CHIP                          ATP    Detergent  Time                       
   1        2         3         4         5          6        7     +        +         +         +         +         +        +      +         ̶          +         +         +       1µg    2µg         ̶         +         +         +         +         +        +      ̶          ̶        T-x        D         ̶            ̶          ̶   50       50      50        50       50       50      50              170 – 
    70 – 
       40 – 
   30 – 
    25 –    
   15 – α-syn 
(UB)n-α-syn 
UB-α-syn 
Lanes  Alpha-synuclein CHIP                          ATP                           Time (min)              
 1        2         3        4        5        6        7        8    ̶         +         +        +        +        +        +        +  +         ̶          +        +        +        +        +        +  +        +          ̶         +        +        +        +        + 50      50       50      10      20       30      40      50 
170 – 100 –    70 –    40 – 
   30 –    25 –     
  15 – 
Figure 26. In vitro ubiquitination of α-synuclein by CHIP with PFA. 
Immunoblot of in vitro ubiquitination reactions assembled using ATP, ubiquitin, Ube1, ubcH5α and alpha synuclein and started with His-CHIP. The samples were incubated from 10 to 50 minutes at 30ºC and the reaction was stopped with the addition of sample buffer. Between transferring and blocking a PFA 30 minute incubation step was added. The results are representative of two independent experiments.  
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 The presence of detergent in the reaction buffer was a factor that had plenty of 
influence in the reaction, decreasing ubiquitination of α-synuclein by CHIP, as can be 
observed in lanes 3 and 4 (Figure 27) when compared with lane 5.  In a previous assay 
(data not shown) CHIP’s autoubiquitination was not affected by the presence of detergent 
suggesting this alteration is dependent on α-synuclein. It is possible that α-synuclein 
conformation is affected by the presence the detergents used influencing its binding to 
CHIP or CHIP’s ability to ubiquitinate it. The following assays were performed without 
detergents in the reaction buffer. 
 Regarding CHIP’s concentration it was decided to continue running the assays with 
3µg of CHIP to guarantee that any changes in the ubiquitination patterns were not due to 
an insufficient amount of the E3 CHIP. 
 
 Afterwards, an ubiquitination assay was conducted using modified ubiquitin in 
which all the reactive lysines residues were mutated to arginine, rendering it unable to form 
poly-ubiquitin chains. Therefore the bands that appear will correspond only to 
monoubiquitinated and multi-monoubiquitinated α-synuclein. 
 
 
 
 
 
 
 
 
 
 
This assay (Figure 28) presents better defined bands, likely because there are less 
ubiquitinated forms of α-synuclein, due to the impossibility to form poly-ubiquitin chains, 
allowing for a clearer signal. This difference in the ubiquitination pattern obtained with the 
use of modified ubiquitin suggests that, in vitro, CHIP is not only capable of 
Figure 28. Time course ubiquitination assay with modified ubiquitin. 
Immunoblot of in vitro ubiquitination reactions assembled using ATP, modified ubiquitin, Ube1, ubcH5α and α-synuclein and started with His-CHIP. The samples were incubated from 15 to 70 minutes at 30ºC and the reaction was stopped with the addition of sample buffer.  
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monoubiquitinating α-synuclein in one and in multiple sites but can also insert poly-
ubiquitin chains. 
Finally, it was investigated whether the presence of α-synuclein had any effect on 
CHIP’s in vitro activity, by looking at CHIP’s autoubiquitination in the presence and 
absence of α-synuclein.  
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
Since CHIP’s autoubiquitination is a very swift process, the incubation times had 
to be reduced in order to make sure that both a decrease and an increase in activity could 
be detected should any occur. The data presented above shows that there is no visible 
difference between CHIP’s autoubiquitination in the presence of α-synuclein and in its 
absence (Figure 29, compare lanes 1, 3 and 5 with lanes 2, 4 and 6) indicating that CHIP’s 
autoubiquitination activity in vitro is not influenced by the presence of this substrate. In the 
future the assay should also be tried with a lower concentration of His-CHIP as the high 
immunoreactivity might be obscuring slighter differences. 
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Figure 29. CHIP autoubiquitination in the presence and absence of α-synuclein. 
Immunoblot of in vitro ubiquitination reactions assembled using ATP, ubiquitin, Ube1, ubcH5α and started with His-CHIP  in the presence or absence of substrate (α-synuclein). Samples were incubated for 1 to 30 minutes at 30ºC and the reaction was stopped with the addition of sample buffer and run in 15% gels. CHIP and α-synuclein were detected with anti-CHIP 3.1 (1:2000) and anti-α-synuclein (1:2000), followed by anti-mouse (1:1000). 
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 Effect of scFvs in CHIP’s ubiquitination activity in vitro 
 After establishing an optimized in vitro ubiquitination system and determining some 
of the particulars of the interaction between CHIP and α-synuclein in those conditions, this 
assay was used to study the effect of the purified scFvs in CHIP’s in vitro activity. To this 
end, a titration of scFv was added to the assay and a control with only the scFv buffer, 
volume matched to the highest concentration in the scFv titration, was included. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial results with scFv 11F purified from TG1 cells showed that this clone was 
capable of inhibiting α-synuclein in vitro ubiquitination by CHIP (Figure 30) as is visible by 
comparing lane 5 (control with scFv buffer) with lanes 6-9.  The ubiquitination bands of 
higher molecular weight are the first ones to be supressed followed by the first band of the 
upper pattern (marked with an arrow), possibly polyubiquitination bands. The bands 
corresponding to monoubiquitinated α-synuclein are the last ones to be inhibited by the 
binding of scFv 11F to CHIP.  
Figure 30. ScFv 11F (TG1) interferes with α-synuclein ubiquitination by CHIP. 
Immunoblot of in vitro ubiquitination reactions assembled using ATP, ubiquitin, Ube1, ubcH5α and α-synuclein. A titration of scFv or scFv buffer was added when indicated immediately before the reaction was started with His-CHIP. Samples were incubated for 30 minutes at 30ºC and the reaction was stopped with the addition of sample buffer and run in 15% SDS-polyacrilamide gels. CHIP and α-synuclein were detected with anti-CHIP 3.1 (1:2000) and anti-α-synuclein (1:2000), followed by anti-mouse (1:1000). 
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It is also curious to note that the presence of the scFv 11F had no effect on CHIP’s 
autoubiquitination suggesting that perhaps these two processes occur by different 
mechanisms. 
An interesting finding was the increased signal of the bands present in the interface 
between the stacking and the resolving gels, in the lanes where scFv were present (lanes 
6-9) when compared with lanes 2, 4 and 5. However they are not present in the absence 
of CHIP or α-synuclein (lanes 1 and 3, respectively). These bands had already appeared 
in several assays throughout this study (Figure 25, Figure 26 and Figure 27) and in others 
that were not included here and will be further investigated in the next chapter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The influence of the scFv 11F, produced from BL21 (DE3) cells, in CHIP’s 
ubiquitination of α-synuclein was also tested and confirmed the results obtained 
previously, as can be seen above (Figure 31) by comparing lanes  6-9 with lane 5 (control 
with scFv buffer) 
Figure 31. ScFv 11F (BL21-DE3) interferes with α-synuclein ubiquitination by CHIP. 
Immunoblot of in vitro ubiquitination reactions assembled as described in Figure 33 but using the batch of scFv 11F obtainedfrom E.coli BL21-DE3. Samples were incubated for 30 minutes at 30ºC and the reaction was stopped with the addition of sample buffer and run in 15% SDS-polyacrilamide gels. CHIP and α-synuclein were detected with anti-CHIP 3.1 (1:2000) and anti-α-synuclein (1:2000), followed bu anti-mouse (1:1000). 
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The influence of the scFv 4C, 7A and 7G in CHIP’s autoubiquitination and α-
synuclein’s ubiquitination was also tested and yielded mostly the same results as 
described for 11F (Figure 32 and 33). The only difference is that for these three clones 
with 0.3ug of scFv (Figure 32 and 33, lane 9) it is still possible to observe a band of 
monoubiquitinated α-synuclein, when for 11F this band is not present (Figure 31, lane 9). 
This may be related to the different affinities the clones present for CHIP with 11F being 
the clones that promotes the most stable binding to CHIP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is also interesting to notice that even though scFv 4C presented the lowest affinity 
for CHIP in the characterization assays (Figures 21 and 22), the results obtained in 
ubiquitination assay (Figure 32) were not very different from the results of scFv 7A and 7G 
(Figure 33) and scFv 11F (Figure 31). This suggests that perhaps the immobilization of 
CHIP to the plate hampers the binding of scFv 4C, maybe hampering its access to the 
epitope. However when both CHIP and scFv 4C are in solution this hindrance is removed 
and so the scFv reactivity towards CHIP increases. 
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Figure 32. ScFv 4C interferes with α-synuclein ubiquitination by CHIP. 
In vitro ubiquitination assay assembled as described above but using the scFv 4C. Samples were incubated for 30 minutes at 30ºC and the reaction was stopped with the addition of sample buffer and run in 15% SDS-polyacrilamide gels. CHIP and α-synuclein were detected with anti-CHIP 3.1 (1:2000) and anti-α-synuclein (1:2000), followed by anti-mouse (1:1000). 
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Figure 33.  Impact of scFvs 7A and 7G CHIP’s ubiquitination activity. 
Western blots of in vitro ubiquitination assay assembled as described above but using the scFvs 7A (A) and 7G (B). Samples were incubated for 30 minutes at 30ºC and the reaction was stopped with the addition of sample buffer and run in 15% SDS-polyacrilamide gels. CHIP and α-synuclein were detected with anti-CHIP 3.1 (1:2000) and anti-α-synuclein (1:2000), followed by anti-mouse (1:1000). 
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 As the purified scFvs interfered with ubiquitination of α-synuclein but not with 
CHIP’s autoubiquitination, the assay was carried out using p53, another substrate of CHIP, 
to see if the scFv also prevented its ubiquitination by CHIP. The assay was carried out as 
the previous ones but using p53 instead of α-synuclein. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
The results show that scFvs 4C and 7A have no effect on p53 ubiquitination by 
CHIP (Figure 34, compare lane 5 with lanes 6-9). When the assay is run with scFv 11F, it 
also seems to have no effect, even though the signal is not so strong in lane 9 compared 
with lanes 5-9; this is most likely related with the running of the gel or the transfer process. 
Summarising, it is interesting to observe that the developed scFv seem to interfere 
only with in vitro α-synuclein ubiquitination by CHIP but not CHIP’s autoubiquitination or 
p53’s ubiquitination indicating that perhaps scFvs interferes with α-synuclein binding to 
CHIP or that these processes occur by different mechanisms. 
Figure 34. ScFvs effect in p53 in vitro ubiquitination by CHIP. 
Immunoblot of in vitro ubiquitination reactions assembled using ATP, ubiquitin, Ube1, ubcH5α and p53. A titration of scFvs 4C (A), 7A (B) or 11F (C), or scFv buffer was added when indicated immediately before The reaction was started with His-CHIP. Samples were incubated for 30 minutes at 30ºC and the reaction was stopped with the addition of sample buffer and run in 12% SDS-polyacrilamide gels. P53 and CHIP were detected with anti-p53 DO1 (1:1000) and anti-CHIP 3.1 (1:2000) followed by anti-mouse (1:1000). 
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 CHIP appears to promote in vitro formation of gel-excluding α-
synuclein bands 
 
The presence of gel-excluding bands of α-synuclein was detected in several 
assays performed during this study (Figures 25-27) but they went mostly unnoticed until 
their presence was reinforced by the presence of the scFv 11F (Figure 30). 
Although these bands are also present in some assays without the scFv, they’re 
usually thinner and partly obscured due to the extension of the ubiquitination pattern that 
usually extends right up to the top of the resolving gel. In fact, before the results shown in 
figure 30, it was believed these bands were probably part of the ubiquitination pattern. 
In order to gain some more insight into the conditions that led to the formation of 
these bands more assays were executed. This proved to be a difficult task due to the 
elusive nature of these bands and the fact that they aren’t always detected however it was 
possible to answer some questions. 
First, it was aimed to confirm that the bands were in fact α-synuclein bands and so 
the ubiquitination reactions were performed with and without α-synuclein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The data above shows that the gel-excluded bands are in fact dependent on the 
presence of α-synuclein (Figure 35, compare lanes 6 and 8 with lanes 7 and 9). However 
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Figure 35. Gel-excluding bands dependence on α-synuclein. 
Immunoblot of in vitro ubiquitination reactions assembled using ATP, ubiquitin, Ube1, ubcH5α and a titration of scFv or scFv buffer was added when indicated immediately before the reaction was started with His-CHIP.  α-synuclein was added only when indicated. Samples were incubated for 30 minutes at 30ºC and the reaction was stopped with the addition of sample buffer and run in 15% SDS-polyacrilamide gels. α-synuclein was detected with anti-α-synuclein (1:2000), followed by anti-mouse (1:1000). The data is represenattive of two independent experiments. 
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once again they are mostly present on the assays where scFv 11F was present, being 
detectable in lanes 3 and 5 only in longer exposures. 
After establishing the bands contained α-synuclein, it was necessary to confirm 
that they were also dependent on the presence of CHIP, as they have never been present 
in the controls without the E3 ligase.  
 
  
 
 
 
 
 
 
 
 
 
 
 
Comparing lanes 6 and 8 with lanes 7 and 9 (Figure 36) demonstrates that the 
presence of the gel-excluded bands is dependent on the presence of CHIP, suggesting 
that, whatever is occurring, the process is catalysed by the E3 ligase. Once again the 
bands were only visible in the presence of scFv 11F. 
Knowing that the bands are α-synuclein and CHIP-dependent it was relevant to 
exclude the bands’ association to the ubiquitination process. This association was unlikely 
given that they seem to be stronger exactly when ubiquitination in inhibited by the scFv 
but to confirm the reactions were performed in the presence and absence of ATP. 
 
 
Figure 36. Identification of gel-excluding bands in the presence and absence of CHIP. 
Immunoblot of in vitro ubiquitination reactions assembled using ATP, ubiquitin, Ube1, ubcH5α and α-synuclein. A titration of scFv or scFv buffer was added when indicated immediately before the reaction was started. His-CHIP was added only to lanes 1, 2, 3, 5, 7, and 9. Samples were incubated for 30 minutes at 30ºC and the reaction was stopped with the addition of sample buffer and run in 15% SDS-polyacrilamide gels. CHIP and α-synuclein were detected with anti-CHIP 3.1 (1:2000) and anti-α-synuclein (1:2000), followed by anti-mouse (1:1000). 
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As described before, the band are missing from the controls without α-synuclein and CHIP 
(Figure 37, lanes 1 and 2); they can be detected in the regular ubiquitination reaction (lane 
3) and in the control with the scFv buffer in the presence and absence of ATP (lanes 4 and 
5) and are present with a stronger signal in the reactions to which scFv was added, both 
with and without ATP (lanes 6-9). 
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Figure 37. Association of gel-excluding bands to the ubiquitination reaction. 
Immunoblot of in vitro ubiquitination reactions assembled using ubiquitin, Ube1, ubcH5α and α-synuclein. A titration of scFv or scFv buffer was added when indicated, immediately before the reaction was started with His-CHIP. ATP was included only in lanes 2-4, 6 and 8. Samples were incubated for 30 minutes at 30ºC and the reaction was stopped with the addition of sample buffer and run in 15% SDS-polyacrilamide gels. α-synuclein were detected with anti-α-synuclein (1:2000), followed by anti-mouse (1:1000). The results are representative of two independent experiments. 
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Figure 38. Dependence of gel-excluding bands on the presence of the ubiquitination assay components. 
Immunoblot of in vitro ubiquitination reactions assembled with α-synuclein, His-CHIP and a titration of scFv 11F or scFv buffer when indicated. ATP, ubiquitin, Ube1 and ubcH5α was only added to reactions in lanes 1-4, 6 and 8. Samples were incubated for 30 minutes at 30ºC and the reaction was stopped with the addition of sample buffer and run in 15% SDS-polyacrilamide gels. α-synuclein was detected with anti-α-synuclein (1:2000), followed by anti-mouse (1:1000). The results are representative of three independent experiments. 
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Finally, it was studied whether the bands were still present if all the components of 
the ubiquitination system (ATP, ubiquitin, E1 and E2) were removed, leaving only α-
synuclein and CHIP to interact in the reaction buffer, alongside scFv 11F. 
The results show that the bands are still present when all the components of the 
ubiquitination system are removed from the reaction (Figure 38, lanes 7 and 9), effectively 
demonstrating that the bands are not associated with the ubiquitination process. The band 
appears to be missing in lane 8 but it more noticeable in higher exposures. 
 
Taking all these results into consideration it is possible to say that CHIP is 
catalysing the development of non ubiquitinated α-synuclein forms that remain caught in 
the interface of the stacking and the resolving gel. Since the bands are usually stronger in 
the presence of the scFv it can be suggested that the lack of ability to ubiquitinate α-
synuclein leads to an increase in the formation of these gel-excluded forms. 
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V. DISCUSSION 
The C-terminus of the Hsc70-Interacting Protein is a complex and interesting 
protein intrinsically involved in the maintenance of the cellular proteome as it bridges the 
molecular chaperones network with the ubiquitin/proteasome system (Ballinger et al., 
1999). This distinctive role places CHIP in the centre of a diverse array of biochemical 
phenomena, both in physiology and disease, motivating the search for a better 
understanding of its function and regulation in order to potentiate its use as a therapeutic 
target. 
Overall, more than sixty substrates have already been described for CHIP and 
evidence, so far, has this peculiar protein involved in several, often contradictory, 
pathways. This observation is intimately related with one of the most prominent question 
in all CHIP-related research which involves substrate specificity. How does CHIP 
discriminate and correctly direct so many different substrates? Which specific details 
motivate these mechanisms? Recent studies involving facilitators of CHIP’s activity, such 
as the chaperones (Soss et al., 2015), and exploring CHIP’s intrinsic dynamics 
(Matsumura et al., 2013; Narayan et al., 2015) are opening the way for a better 
understanding of these concepts and the development of new strategies that can be 
applied in this endeavour are welcome. 
 At the same time, scFvs and its multimeric formats continue to emerge as powerful 
tools not just for detection and imaging but also as research instruments and therapeutic 
solutions. Initially these fragments were produced from hybridoma cell lines however that 
process was expensive and slow (McCafferty et al., 1990) so new technologies were 
developed. Phage display is, to date, the most used molecular display system to select 
scFvs and potentiated their use and development. Nowadays, the simple and inexpensive 
production process coupled with the small size and ease of tailoring and manipulation of 
these fragments puts them in the frontline for a growing range of applications (Monnier et 
al., 2013). 
  In this study, wild type His-tagged CHIP and mutant CHIP K30A were used to screen 
a canine scFv antibodies phage display library. Phage selection was carried out with the 
targets directly bound to microtiter plate wells as this method is easy to perform and has 
been widely successful (Winter et al., 1994). For both targets three rounds of panning were 
enough to successfully obtain polyclonal phage pools with increased specificity for CHIP 
as increasingly stringent washing conditions during panning eliminated non-specific and 
weak binders.  
 The resulting His-CHIP and CHIP-K30A libraries were used to grow randomly select 
clones and the functionality and affinity of the scFvs for the respective target were tested. 
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From this process 14 clones emerged as possible good binders with the clone 11F clearly 
appearing as a very strong candidate, even though the signals were subjected to 
expression bias. 
 These clones were then further validated and a higher binding affinity for the mutant 
CHIP-K30A was detected. This is in line with a recent publication that studied this mutant 
alongside wild type CHIP and found it lacking in motion and flexibility (Narayan et al., 
2015). Considering the new ensemble model of allostery, that supports the presence of 
different structural species of one protein in solution at one time (Motlagh et al., 2014), it 
is reasonable to assume the mutant is limited when it comes to the conformations it can 
adopt in solution when compared with the wild type protein. This may potentiate the 
formation of more stable complexes with the scFv, resulting in a higher binding signal. 
 The most promising clones were sent for sequencing to ensure that only clones with 
different sequences would be taken forward and 8 different clones were obtained. As 
expected, the framework regions showed high similarity between the clones and the heavy 
chain CDRs were shared by several of the clones while the light chains were different for 
all. Finally the eight clones were shown to be able to bind to untagged CHIP, possibly a 
closer form to endogenous CHIP, with appreciable affinity. 
 Four of the above clones (4C, 7A, 7G and 11F) were successfully produced and 
purified from E.coli and characterized according to their binding to CHIP and the mutant. 
These clones, now free from expression bias, showed different binding affinities for the 
targets with 11F standing out as the strongest binder followed by 7G and 7A and lastly 4C. 
It was also interesting to notice that unlike the other clones 7G was capable of binding to 
both the mutant and wild type CHIP with similar affinity suggesting that it may bind to an 
epitope less susceptible to change in the different conformations CHIP may be able to 
adopt in solution. Conversely 7A shows the biggest difference in binding between the two 
forms while still being unspecific for either.  
 An attempt to identify the binding epitopes of the scFv through peptide binding 
assays with CHIP peptides was made but the results were inconclusive or irreproducible 
(data not shown). So in order to gain some insight into the binding interfaces of the scFv 
with CHIP the complexes were analysed in a native gel. Curiously the binding of 11F and 
7G gave CHIP a higher mobility on the gel and lower bands were observed. This raises 
the possibility the scFv can interfere with the assembly of CHIP monomers, inhibiting 
dimerization, and reinforces the supposition that these scFvs may bind to different 
epitopes 
  
 ScFvs have been shown to interfere and modulate the activity of proteins both in 
vitro an in vivo (Moller et al., 2010; Basu et al., 2012), alter intracellular location of the 
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targets (Bai et al., 2003) or disrupt interactions protein-protein (Visintin et al., 2008). All 
these strategies can be used not only in the development of therapies but also to help 
study the functions of the scFvs’ targets or the importance of different protein domains. 
 The main goal of this study was to select scFv antibodies that would not only allow 
the detection of CHIP and could be used in imaging solutions but also that could modulate 
the activity of this E3 ligase.  
 To this end, an in vitro ubiquitination assay was established as a model that would 
allow the study of the scFvs impact on the activity of CHIP. The chosen substrate was α-
synuclein, a 15kDa protein whose physiological functions still haven’t been completely 
elucidated but whose aggregates have been associated with Parkinson’s disease 
(Polymeropoulos et al., 1996). Alpha-synuclein undergoes CHIP-mediated degradation in 
vivo (Dimant et al., 2014) and has been found to co-localize with CHIP and Hsp70 in Lewy 
bodies (Spillantini et al., 1997) revealing itself as relevant substrate. 
 The addition of a PFA incubation step in the conventional western blot procedure 
was necessary to stop ubiquitinated α-synuclein species from washing away. It has been 
shown that the use of small concentrations of PFA prevents the washing off of endogenous 
α-synuclein monomers from the blotting membranes (Newman et al., 2013). In this case, 
the monomers were very immunoreactive and the absent bands were the ubiquitinated 
forms. It is possible that the binding of the ubiquitinated α-synuclein to the membrane is 
more unstable, causing the species to be washed off during the numerous washing steps 
of the Western blot procedure.  
 The presence of detergents such as Tríton-X seemed to decrease ubiquitination of 
α-synuclein by CHIP. Alpha-synuclein is usually considered an intrinsically disordered 
protein however, in the presence of lipids and detergents, it has been shown to adopt a 
more helical structure at the N-terminal region (Chandra et al., 2003). Perhaps the 
detergent-induced helical structure of α-synuclein decreased ubiquitination by CHIP by 
altering the stability of the binding between the two proteins.  
 This study demonstrated that direct binding of CHIP to α-synuclein was sufficient 
to signal mono-, poly- and multi-monoubiquitination without additional cellular 
components, such as Hsp70. This observation agrees with several studies in which direct 
interaction of CHIP with its substrates has been reported (McDonough et al., 2009; Shang 
et al., 2009; Narayan et al., 2011).  
  Upon inclusion of a titration of scFvs in the assay, it was revealed that the four 
clones appear to inhibit α-synuclein ubiquitination by CHIP, in a concentration dependent 
manner, however there was no decrease in CHIP’s autoubiquitination. Additionally, the 
assay was performed with p53, another known substrate of CHIP, and it was shown the 
ubiquitination had not been affected by the scFvs either. This would suggest that either 
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the scFv fragments are blocking the binding site of α-synuclein in CHIP, and both p53 and 
CHIP itself bind to another domain, or the scFvs are producing changes in CHIP that stop 
it from ubiquitinating α-synuclein while p53 ubiquitination and CHIP’s autoubiquitination 
occur by a different mechanism and are not affected. However, the fact that 11F and 7G 
induce an apparent monomerization of CHIP also needs to be considered along with the 
observation that this held no effect on CHIP and p53 in vitro ubiquitination. This could be 
a very relevant finding seeing as dimerization has been considered a requirement for 
CHIP’s activity as an E3 ligase (Nikolay et al., 2004).  
 It is also curious that the four scFvs seem to produce the same effect in CHIP’s 
activity although they seem to provoke different alterations in CHIP itself. Since these 
molecular mechanisms haven’t been well explored and the binding interfaces of these 
substrates to CHIP as well as the epitopes of the scFvs are still to be determined it is not 
yet possible to draw a more conclusive interpretation of these results.     An interesting observation of this study was the appearance of gel-excluding bands 
on western blots revealed with anti-α-synuclein. It was shown these bands were α-
synuclein and CHIP dependent but not dependent on the ubiquitination reaction. In some 
blots these bands were enhanced in the presence of scFv 11F. So it seems that CHIP is 
capable of producing other alterations on α-synuclein besides ubiquitination. Inclusively, 
this activity seems to be stimulated once the ubiquitination is blocked. 
 One of the possible explanations is that CHIP is promoting the formation of α-
synuclein aggregates. This might seem a bit unlikely as CHIP is an important enzyme 
involved in the maintenance of the proteome integrity and its main functions are assisting 
chaperones in the folding of misfolded or unfolded proteins or directing them to the 
ubiquitin/proteasome pathway. However this would not be the first contradictory role CHIP 
would have as it has been shown to function as both a tumour suppressor (Bento et al., 
2010; Su et al., 2013; Wang et al., 2014b) and an oncogene (Li et al., 2009; Ahmed et al., 
2012). In fact CHIP has been shown to promote aggregation of ataxin-1 by a TPR-
dependent mechanism. While CHIP’s primary role towards ataxin-1 is to mediate its 
ubiquitination, this modification along with the innate tendency of misfolded ataxin-1 to 
aggregate promotes the accumulation of detergent insoluble aggregates, when CHIP is 
overexpressed (Choi et al., 2007). This ubiquitination dependent aggregation has already 
been shown for tau (Petrucelli et al., 2004) and nNOS (Peng et al., 2004) and was 
ameliorated by overexpression of Hsc/Hsp70. The only detail against this theory is the fact 
that in this study α-synuclein was not ubiquitinated. 
 Another possible explanation could be that CHIP is folding α-synuclein. Although 
CHIP is better known for its role as a co-chaperone, it has been reported it also possesses 
intrinsic chaperone activity. This hypothesis was first suggested when overexpression of 
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CHIP in cultured cells was shown to enhance refolding of stress damaged proteins 
(Kampinga et al., 2003). Later another study investigated whether CHIP had the ability to 
function as an autonomous molecular chaperone and found that CHIP has intrinsic 
chaperone activity, enhanced by heat stress, which enables it to bind to non native 
substrates through the TPR domain (Rosser et al., 2007).  CHIP’s chaperoning activity 
has also been demonstrated for wild type p53 both in vitro and in vivo (Tripathi et al., 2007). 
Considering that α-synuclein is usually intrinsically disordered it is plausible that CHIP 
would attempt to fold it, especially when ubiquitination is inhibited, providing an alternate 
pathway to respond to cellular stress.    Broadening the range of strategies available to study a system always opens the 
door for new possibilities. In this project, Phage Display has proven to be a very suitable 
method to successfully select high affinity scFv binders for WT CHIP and the mutant K30A. 
These scFv were characterized as having different affinities for the targets which can be 
useful for different future applications. The scFvs’ specificity for CHIP allows their use for 
detection and prospective imaging techniques while their capacity to modulate CHIP’s 
activity opens the doors for the possible application of these biological tools in 
therapeutics. 
 CHIP is a protein tightly wrapped in layers of regulation and its activity is dependent 
on different molecular mechanisms still largely unidentified. Before the jump to therapeutic 
applications can find solid ground there is still a lot to be known about this protein and the 
processes it is involved in, especially considering the opposite roles it can take on. Until 
regulation and mechanistics of those roles are clarified it would be easy to interfere with 
more than one pathway simultaneously. 
This project has also shown that scFvs can be a useful tool to gain new insight into 
possible differences in CHIP’s molecular mechanisms, substrate selection and regulation 
of less known functions. Once the epitopes of the selected single chains are mapped more 
conclusions can be drawn from this study, as the information will shed light into some of 
differences observed and possibly open new research paths. 
 Future perspectives include the characterization of the scFv with endogenous 
CHIP and expression in mammalian cells to assess the intracellular functionality of the 
scFvs. Another possibility is the development of imaging applications probably involving 
fluorescence-based techniques. Additionally these scFvs can be used to keep studying 
CHIP’s intrinsic mechanics and new scFvs can be developed against specific domains of 
the protein.  
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